WO2025070636A1 - Cd39を標的とする多重特異性抗原結合性分子 - Google Patents

Cd39を標的とする多重特異性抗原結合性分子 Download PDF

Info

Publication number
WO2025070636A1
WO2025070636A1 PCT/JP2024/034478 JP2024034478W WO2025070636A1 WO 2025070636 A1 WO2025070636 A1 WO 2025070636A1 JP 2024034478 W JP2024034478 W JP 2024034478W WO 2025070636 A1 WO2025070636 A1 WO 2025070636A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
binding
acid sequence
binding domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/034478
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
元弥 三重
款冬 中島
峻彦 荒牧
悠太 大平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BrightPath Biotherapeutics Co Ltd
Original Assignee
BrightPath Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BrightPath Biotherapeutics Co Ltd filed Critical BrightPath Biotherapeutics Co Ltd
Priority to JP2025549115A priority Critical patent/JPWO2025070636A1/ja
Publication of WO2025070636A1 publication Critical patent/WO2025070636A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the technical field of the present invention relates to CD39 binding domains or multispecific antigen-binding molecules that target CD39.
  • CD39 is a two-pass transmembrane glycoprotein that has been reported to be expressed in cancer cells, such as lung cancer, gastric cancer, ovarian cancer, and melanoma (e.g., Non-Patent Documents 1 and 2).
  • Patent Documents 1 and 2 describe antibodies that bind to CD39 and antibodies that have the ability to inhibit CD39 enzyme activity.
  • bispecific antibodies e.g., non-patent documents 3 to 12
  • a technique is known in which a bispecific antibody that binds to a cancer cell surface antigen (e.g., CD19) and a T cell surface antigen (e.g., CD3) is administered to a patient to attract T cells to the vicinity of cancer cells, allowing the T cells to effectively kill the cancer cells.
  • a cancer cell surface antigen e.g., CD19
  • T cell surface antigen e.g., CD3
  • Non-Patent Document 3 more than 140 different molecules are in clinical trials, and Figure 1 and Table 1 in Non-Patent Document 3 list many formats of multispecific antibodies in clinical trials.
  • Multispecific antigen-binding molecules approved in the United States for cancer treatment include blinatumomab, teclistamab, and tebentafusp.
  • Blinatumomab is a bispecific antibody that targets CD19 on malignant B cells, with the CD19-binding domain and the CD3-binding domain linked via a linker.
  • Teclistamab is a bispecific antibody that targets BCMA on myeloma cells, with the BCMA-binding domain and the CD3-binding domain linked via an Fc region.
  • Tebentafsp is a bispecific fusion protein that targets gp100 on melanoma, with the gp100-binding domain and the CD3-binding domain linked via a linker.
  • CD39 is expressed on cancer cells.
  • the present inventors have created a novel specific CD39-binding domain and prepared a multispecific antigen-binding molecule having the CD39-binding domain.
  • a multispecific antigen-binding molecule was obtained that has excellent one or more properties, such as affinity for CD39 on the membrane of cancer cells, or antitumor activity or cytokine production activity associated with engagement between cancer cells and immune cells.
  • the present invention aims to provide a novel CD39-binding domain that can be used to create a multispecific antigen-binding molecule that targets CD39 on cancer cells, or an object or method that utilizes the CD39-binding domain.
  • a CD39-binding domain comprising: (a) a heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 2, a heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 3, a light chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 6; (b) a CD39-binding domain comprising a heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO:7, a heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO:8, a heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO:9, a light chain CDR1 comprising the amino acid sequence shown in SEQ ID NO:10, a light chain
  • a polynucleotide or vector that encodes a multispecific antigen-binding molecule comprising a CD39-binding domain comprising any one of heavy chain CDR1-3 and light chain CDR1-3 of (a) to (d) above.
  • a cell is provided that comprises the polynucleotide or vector above.
  • a method for producing a multispecific antigen-binding molecule is provided that comprises a step of growing the cell above.
  • a composition is provided that comprises the multispecific antigen-binding molecule above.
  • a pharmaceutical composition for treating malignant tumors comprises the multispecific antigen-binding molecule above.
  • a composition for promoting cytokine production by immune cells is provided that comprises the multispecific antigen-binding molecule above.
  • a kit is provided that comprises the multispecific antigen-binding molecule above.
  • This figure shows the results of epitope binning of anti-human CD39 antibodies.
  • Epitope binning was performed using Biacore 8K.
  • the antibodies listed vertically in Figure 1 ( 1st Ab) and then the antibodies listed horizontally in Figure 1 ( 2nd Ab) were applied to a Ni-NTA sensor chip that captured recombinant human CD39 antigen, and the presence or absence of a response associated with the binding of the 2nd Ab was evaluated. Combinations that did not show a response are shown in dark gray, and combinations that showed a response are shown in white. Combinations that showed differences in response when the order of application was changed are shown in light gray. Clones that showed similar competition were grouped together and classified into four bins.
  • This figure shows the results of affinity measurement of anti-human CD39 antibodies for recombinant antigens by surface plasmon resonance.
  • Each anti-human CD39 antibody was captured on a CM5 sensor chip using the Human Antibody Capture Kit (Cytiava), and recombinant human CD39 prepared in five 2-fold dilution series starting from 50 nM or 12.5 nM was run as the analyte.
  • the association rate (ka) and dissociation rate (kd) were calculated using a simple one-to-one Langmuir binding model.
  • the equilibrium dissociation constant (KD) was calculated as the ratio kd/ka. 1 shows the results of measuring the binding of anti-human CD39 antibodies to antigens on cell membranes.
  • the binding of each anti-CD39 antibody to HEK293T cells stably expressing human CD39 was measured by flow cytometry, and the mean fluorescence intensity was plotted against the antibody concentration.
  • the bispecific molecule was designed to have a first antigen-binding domain (CD39-binding domain) targeting human CD39 and a second antigen-binding domain (4-1BB-binding domain) targeting human 4-1BB, an immune cell surface antigen.
  • the first antigen-binding domain was an anti-human CD39 antibody in scFv format.
  • the second antigen-binding domain was a trimer of the extracellular domain of human 4-1BBL.
  • a hole mutation was introduced into the Fc region of the polypeptide chain containing the first antigen-binding domain (Hole-mutated Fc region: SEQ ID NO: 38) out of Knob-into-Hole (US7183076B2, Knob: Seq No. 2, Hole: Seq No. 3), and a knob mutation was introduced into the Fc region of the polypeptide chain containing the second antigen-binding domain (Knob-mutated Fc region: SEQ ID NO: 45).
  • This figure shows the results of affinity measurement of bispecific molecules for human CD39 and 4-1BB by surface plasmon resonance.
  • Each bispecific molecule was captured on a CM5 sensor chip using the Human Antibody Capture Kit, and recombinant human CD39 was prepared as an analyte at five 2-fold dilution levels starting from 50 nM or 12.5 nM, and recombinant human 4-1BB was prepared as an analyte at four 4-fold dilution levels starting from 2 uM.
  • the association rate (ka) and dissociation rate (kd) were calculated using a simple one-to-one Langmuir binding model.
  • the equilibrium dissociation constant (KD) was calculated as the ratio kd/ka.
  • Binding of bispecific molecules to a human cancer cell line was measured by flow cytometry, and mean fluorescence intensity was plotted against antibody concentration. Binding of bispecific molecules to a human cancer cell line (SKMEL28) was measured by flow cytometry, and mean fluorescence intensity was plotted against antibody concentration. This figure shows the results of measuring the ability of bispecific molecules to inhibit human CD39 enzyme activity.
  • OAW42 cells were seeded in a 96-well plate at 6.25x103 cells/well, and serially diluted bispecific molecules were added. ATP was further added, and the amount of ATP remaining in the supernatant after 30 minutes was quantified using CellTiter-Glo® 2.0 (Promega, G9242).
  • the ATP remaining value of the wells in which cells were not seeded was set to 100%, and the ATP remaining value of the wells in which cells were seeded and no antibody was added was set to 0%, and the inhibition rate of ATP decomposition in each bispecific molecule was calculated from the ratio of the ATP remaining value of the measurement sample.
  • This figure shows the results of measuring the amount of cytokine production in a co-culture system of cancer cells and PBMCs. SKMEL28 cells irradiated with 50 Gy of X-rays were seeded as target cells at 2x104 cells/well in a 96-well plate, and PBMCs were added as effector cells so that the effector cell/target cell ratio (E/T) was 10.
  • wells were prepared to contain only effector cells.
  • 10ug/mL of each bispecific molecule and 1nM of anti-human CD3 antibody (OKT3) were added and incubated at 37°C for 2 days. After 2 days, the culture supernatant was collected and the cytokine (IL-2, TNF- ⁇ , and IFN- ⁇ ) concentrations were measured using Luminex.
  • IL-2, TNF- ⁇ , and IFN- ⁇ cytokine
  • Each anti-human CD39 antibody was captured on a CM5 sensor chip using the Human Antibody Capture Kit, and recombinant human CD39 prepared in five 2-fold dilution series starting from 40 nM or 10 nM was run as analyte.
  • the association rate (ka) and dissociation rate (kd) were calculated using a simple one-to-one Langmuir binding model.
  • the equilibrium dissociation constant (KD) was calculated as the ratio kd/ka.
  • Figure 1 shows the results of binding analysis of humanized anti-human CD39 antibodies to antigens on cell membranes.
  • Binding of each anti-CD39 antibody to HEK293T cells stably expressing human CD39 was measured by flow cytometry, and the mean fluorescence intensity was plotted against the antibody concentration.
  • This figure shows the results of affinity measurement of bispecific molecules for human CD39 and 4-1BB by surface plasmon resonance.
  • Each bispecific molecule was captured on a CM5 sensor chip using the Human Antibody Capture Kit, and recombinant human CD39 was prepared as an analyte at five 2-fold dilution levels starting from 50 nM or 12.5 nM, and recombinant human 4-1BB was prepared as an analyte at four 4-fold dilution levels starting from 2 uM.
  • association rate (ka) and dissociation rate (kd) were calculated using a simple one-to-one Langmuir binding model.
  • the equilibrium dissociation constant (KD) was calculated as the ratio kd/ka.
  • Binding of bispecific molecules to a human cancer cell line (OAW42) was measured by flow cytometry, and mean fluorescence intensity was plotted against antibody concentration.
  • Binding of bispecific molecules to a human cancer cell line (SKMEL28) was measured by flow cytometry, and mean fluorescence intensity was plotted against antibody concentration. This figure shows the results of measuring the amount of IL-2 produced in a co-culture system of cancer cells and PBMCs.
  • SKMEL28 cells were seeded as target cells in a 96-well plate at 2x104 cells/well, and PBMCs were added as effector cells so that the effector cell/target cell ratio (E/T) was 1.6.
  • wells were prepared to contain only effector cells.
  • 1ug/mL of each bispecific molecule and 1nM of anti-human CD3 antibody (OKT3) were added, and the wells were incubated at 37°C for 4 or 6 days. After incubation, the culture supernatant was collected and the IL-2 concentration was measured using Luminex.
  • FIG. 16 is a diagram summarizing the experimental conditions and P values for measuring cytokine production levels in FIGS. This figure shows the results of measuring the effect of bispecific molecules on the inhibition of cancer cell proliferation.
  • SKMEL28 cells were seeded on a 96-well plate at 4 x 103 cells/well, and PBMCs were added as effector cells so that the effector cell/target cell ratio (E/T) was 2.
  • FIG. 20 is a diagram summarizing the P values in the measurement results of the proliferation inhibitory effect in FIG. 19.
  • FIG. 1 shows the amino acid sequences of the CDRs of the molecules used in the Examples.
  • FIG. 1 shows the amino acid sequences of the variable regions of the molecules used in the Examples.
  • FIG. 1 shows the amino acid sequences of the Fc regions of the molecules used in the Examples.
  • FIG. 1 shows the amino acid sequences of each region of the molecules used in the Examples.
  • FIG. 1 shows the amino acid sequences of each region of the anti-CD3 antibody used in the Examples.
  • This figure shows the results of affinity measurement of bispecific molecules for recombinant antigens by surface plasmon resonance.
  • the bispecific molecules were captured onto a CM5 sensor chip using the Human Antibody Capture Kit (Cytiava), and recombinant human CD39 prepared in five 2-fold dilution series starting from 50 nM or 12.5 nM was run as the analyte.
  • association rate (ka) and dissociation rate (kd) were calculated using a simple one-to-one Langmuir binding model.
  • the equilibrium dissociation constant (KD) was calculated as the ratio kd/ka.
  • Binding of bispecific molecules to a human cancer cell line (SKMEL28) was measured by flow cytometry, and mean fluorescence intensity was plotted against antibody concentration. This figure shows the results of measuring the effect of bispecific molecules on the inhibition of cancer cell proliferation.
  • SKMEL28 cells were seeded on a 96-well plate at 4 x 103 cells/well, and PBMCs were added as effector cells so that the effector cell/target cell ratio (E/T) was 2.
  • SKMEL28 cells were seeded as target cells in a 96-well plate at 2x104 cells/well, and PBMCs were added as effector cells so that the effector cell/target cell ratio (E/T) was 1.6.
  • wells were prepared to which only effector cells were added.
  • 1ug/mL of each bispecific molecule and 1nM of anti-human CD3 antibody (OKT3) were added, and the wells were incubated at 37°C for 4 or 6 days. After incubation, the culture supernatant was collected, and the concentrations of IL-2, TNF- ⁇ , and IFN- ⁇ were measured using Luminex.
  • FIG. 29 shows the results of measuring the amount of Granzyme B or Perforin produced in a co-culture system of cancer cells and PBMCs.
  • a MILLIPLEX MAP 7-Plex Human CD8+/Cytokine Magnetic Bead Panel (Millipore, #HCD8MAG15K17PMX) was used to measure the concentration.
  • the total numbers of CD4-positive T cells and CD8-positive T cells were calculated by flow cytometry analysis, and each was classified according to the expression patterns of CD39 and PD1.
  • a novel CD39 binding domain, or a multispecific antigen-binding molecule comprising a novel CD39 binding domain
  • the CD39 binding domain comprising: (a) a heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 2, a heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 3, a light chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 6; (b) a heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 7, a heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 8, a heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO: 9, a light chain CDR1 comprising:
  • the CD39 includes a protein also known as ENTPD1 or Ectonucleoside triphosphate diphosphohydrolase 1.
  • CD39 can be expressed on the surface of cancer cells. Details of the amino acid sequence of CD39 can be confirmed on websites such as NCBI or UniProt. The primary accession number of CD39 listed in UniProt is, for example, P49961. The amino acid sequence of human CD39 is, for example, SEQ ID NO: 61. The organism of origin of CD39 is not limited as long as it has CD39 activity.
  • CD39 activity includes, for example, ATP decomposition activity, ADP decomposition activity, or ATP or ADP to AMP conversion activity.
  • CD39 activity may be evaluated by incubating CD39 in an environment where it can come into contact with ATP and measuring the amount of ATP reduction.
  • the amount of ATP reduction may be evaluated by measuring chemiluminescence using, for example, CellTiter-Glo (Promega).
  • CD39 includes, for example, human or monkey-derived CD39.
  • the anti-tumor effect of the multispecific antigen-binding molecule may be due to, for example, immune cells being attracted to the vicinity of cancer cells by the multispecific antigen-binding molecule that binds to CD39 (a cancer cell surface antigen) and an immune cell surface antigen, and the cancer cells being killed by the immune cells.
  • Such engagement between cancer cells and immune cells has been shown to kill cancer cells, for example, in Elshiaty et al., Int J Mol Sci. 2021 May 26;22(11):5632., Li et al., Cell Mol Immunol. 2020 May;17(5):451-461., Wei et al., Front Immunol.
  • the anti-tumor effect of the multispecific antigen-binding molecule may result from, for example, trapping the anti-inflammatory cytokine by the multispecific antigen-binding molecule that binds to CD39 (a cancer cell surface antigen) and the anti-inflammatory cytokine, thereby reducing the signaling of the anti-inflammatory cytokine in the tumor microenvironment.
  • This signaling includes, for example, a signal that induces regulatory T cells.
  • Such anti-tumor effect may utilize mechanisms and formats such as those described in, for example, Knudson et al., Oncoimmunology. 2018; 7(5): e1426519., Chen et al., Mol Ther Oncolytics. 2021 Apr 2; 21: 144-157., or Elshiaty et al., Int J Mol Sci. 2021 May 26; 22(11): 5632.
  • the multispecific antigen-binding molecule may be produced, for example, by the Knobs-into-Holes (KIH) method, the quadroma technique, the CrossMAb technique, or the co-culture method.
  • the method for producing the multispecific antigen-binding molecule, including these production methods may be, for example, the method described in Wang et al., Antibodies (Basel). 2019 Aug 2; 8(3): 43., Brinkmann et al., MAbs. 2017 Feb/Mar; 9(2): 182-212., or Klein et al., MAbs. 2012 Nov 1; 4(6): 653-663.
  • a recombinant antibody chain is expressed in which a knob mutation is introduced into one of the heavy chains and a hole mutation is introduced into the other.
  • a knob mutation is introduced into one of the heavy chains and a hole mutation is introduced into the other.
  • heterodimers are preferentially produced.
  • a bispecific antibody in an IgG-like format one or two of the two Fabs linked to the Fc region can be replaced with an scFv, a polypeptide containing a ligand for an antigen or an antigen-binding fragment thereof, or a polypeptide containing a receptor for an antigen or an antigen-binding fragment thereof.
  • the KIH method may utilize, for example, the method described in US7183076 B2.
  • the multispecific antigen-binding molecule includes a molecule that has binding affinity to multiple different antigens.
  • the multispecific antigen-binding molecule includes, for example, a bispecific antigen-binding molecule or a trispecific antigen-binding molecule.
  • the multispecific antigen-binding molecule includes, for example, a multispecific antibody or a multispecific fusion protein.
  • the multispecific antibody includes, for example, a bispecific antibody or a trispecific antibody.
  • the multispecific fusion protein includes, for example, a bispecific fusion protein or a trispecific fusion protein. Multispecific includes specificity for two or more different antigens, bispecific includes specificity for two different antigens, and trispecific includes specificity for three different antigens.
  • the CD39-binding domain is preferably a CD39-binding domain that includes the CDR set (a) or (b) above.
  • a more excellent multispecific antigen-binding molecule can be obtained in terms of high affinity to CD39 on the cancer cell membrane, high antitumor activity associated with engagement between cancer cells and immune cells, or high cytokine production activity associated with engagement between cancer cells and immune cells.
  • the CD39-binding domain is a CD39-binding domain that includes the CDR set (b) above.
  • a more excellent multispecific antigen-binding molecule can be obtained in terms of high affinity to CD39 on the cancer cell membrane, high antitumor activity associated with engagement between cancer cells and immune cells, or high cytokine production activity associated with engagement between cancer cells and immune cells. It is also superior in terms of suppressing side effects (e.g., neutropenia) caused by CD39 enzyme inhibition.
  • the CD39-binding domain preferably has binding ability to CD39 on the surface of cancer cells.
  • Methods for evaluating the binding ability of a CD39-binding domain include evaluating binding to recombinant CD39 (e.g., affinity analysis using surface plasmon resonance or ELISA) and evaluating binding to CD39 on the cell surface (e.g., evaluating binding to forced CD39-expressing cells or CD39-expressing cancer cells). The latter method of evaluating CD39 better reflects the state in the body, and is therefore more suitable as a target for multispecific antigen-binding molecules.
  • the CD39 binding domain includes a domain that includes a heavy chain variable region and a light chain variable region.
  • any one of the CDR sets (a) to (d) above is contained within the heavy chain variable region and the light chain variable region.
  • the CD39 binding domain may be a humanized CD39 binding domain.
  • the humanized domain may, for example, have an amino acid sequence other than the CDRs that is derived from a human immunoglobulin.
  • the humanized domain may, for example, have one or more CDRs from a non-human species and a framework region from a human immunoglobulin, and may include a domain that binds to a desired antigen.
  • the humanization of the domain may be carried out, for example, by a procedure such as that described in Example 3.1 below.
  • Various other techniques known in the art may also be used (e.g., Safdari et al., Biotechnol Genet Eng Rev. 2013;29:175-86.).
  • the method for producing the above CD39 binding domain or a polypeptide comprising a CD39 binding domain is not particularly limited, but can be produced, for example, through a process of: (i) designing an antibody variable region sequence (e.g., a humanized antibody variable region sequence) comprising any of the above CDR sets (a) to (d) using modeling/simulation software (e.g., BIOVIA Discovery Studio 2020 (Dassault Systems)); (ii) incorporating the antibody variable region sequence into an expression vector (optionally encoding a constant region (e.g., a human constant region)); (iii) transfecting the expression vector into a cell; or (iv) recovering and purifying the polypeptide comprising the antibody variable region from the cell.
  • an antibody variable region sequence e.g., a humanized antibody variable region sequence
  • an expression vector optionally encoding a constant region (e.g., a human constant region)
  • transfecting the expression vector into a cell e.g., a human
  • the CD39-binding domain or a polypeptide comprising a CD39-binding domain may be produced by grafting any one of the CDR sets (a) to (d) above onto an existing antibody sequence using a grafting technique such as that described in Safdari et al., Biotechnol Genet Eng Rev. 2013;29:175-86.
  • the CD39-binding domain may be produced by immunizing a mammal with CD39 and obtaining anti-CD39 antibody cells.
  • the CD39-binding domain may be produced by screening the polypeptides based on their binding strength to CD39 or their ability to inhibit CD39 activity.
  • the CDRs, variable regions, Fc regions, or constant regions are typically regions derived from an antibody.
  • the CD39-binding domain may comprise, for example, an antibody (e.g., a full-length antibody, scFv, or Fab).
  • the multispecific antigen-binding molecule includes a multispecific antigen-binding molecule having antitumor activity.
  • This antitumor activity includes antitumor activity resulting from the binding of the multispecific antigen-binding molecule to multiple types of antigens.
  • This antitumor activity includes antitumor activity resulting from the binding of the multispecific antigen-binding molecule to CD39 on the surface of cancer cells, and to immune cell surface antigens or anti-inflammatory cytokines.
  • This antitumor activity includes, for example, cytotoxic activity.
  • the antitumor activity does not need to include activity resulting from the binding of an Fc region to an Fc receptor.
  • the multispecific antigen-binding molecule includes a multispecific antigen-binding molecule capable of activating immune cells (e.g., T cells). Activation of immune cells includes promotion of cancer immune responses.
  • the multispecific antigen-binding molecule includes a multispecific antigen-binding molecule that has binding affinity to a first antigen (e.g., CD39) and has binding affinity to a second antigen (e.g., an antigen other than CD39).
  • the multispecific antigen-binding molecule includes a multispecific antigen-binding molecule that has a domain that has binding affinity to the first antigen and includes a domain that has binding affinity to the second antigen.
  • the second antigen includes, for example, an immune cell surface antigen or an anti-inflammatory cytokine.
  • the multispecific antigen-binding molecule includes a multispecific antigen-binding molecule comprising a first binding domain and a second binding domain.
  • the multispecific antigen-binding molecule includes, for example, a multispecific antigen-binding molecule comprising the CD39-binding domain as the first binding domain and an immune cell surface antigen-binding domain or an anti-inflammatory cytokine-binding domain as the second binding domain.
  • a linker may be present between the first binding domain and the second binding domain.
  • the first binding domain and the second binding domain may be linked via an Fc region.
  • the first binding domain and the second binding domain may be linked via a disulfide bond.
  • the second binding domain may have the ability to activate immune cells (e.g., T cells).
  • the immune cells include, for example, lymphocytes, monocytes, NK cells, NKT cells, dendritic cells, or granulocytes.
  • Lymphocytes include, for example, T cells or B cells.
  • T cells include, for example, killer T cells, helper T cells, regulatory T cells, or ⁇ T cells.
  • Granulocytes include, for example, eosinophils, basophils, or neutrophils.
  • Immune cell surface antigens include antigens expressed on one or more of these immune cells.
  • the immune cell surface antigen includes, for example, a costimulatory molecule, an immune checkpoint molecule, or CD3.
  • the costimulatory molecule includes, for example, 4-1BB, GITR, CD27, CD40, or NKp30.
  • the immune checkpoint molecule includes, for example, TIM-3, LAG-3, BTLA, CTLA-4, or CD73.
  • the immune cell surface antigen binding domain includes a domain that has binding affinity to one or more of these immune cell surface antigens.
  • the immune cell surface antigen includes, for example, a molecule that activates an immune cell (e.g., a T cell).
  • the anti-inflammatory cytokine includes, for example, a molecule that induces regulatory T cells (Treg).
  • the anti-inflammatory cytokine includes, for example, TGF ⁇ , IL-4, IL-10, or IL-11.
  • Treg can be induced to differentiate from naive T cells in peripheral blood by, for example, antigen stimulation in the presence of an anti-inflammatory cytokine (e.g., TGF ⁇ ).
  • the multispecific antigen-binding molecule includes, for example, a multispecific antigen-binding molecule that includes the CD39-binding domain as a first binding domain and a 4-1BB, GITR, CD27, CD40, NKp30, TIM-3, LAG-3, BTLA, CTLA-4, CD73, CD3, or TGF ⁇ -binding domain as a second binding domain.
  • a multispecific antigen-binding molecule having particularly excellent antitumor activity can be obtained.
  • the above 4-1BB includes a protein also known as CD137.
  • 4-1BB is a costimulatory molecule belonging to the TNF receptor family, and has been reported to be involved in the activation and survival of T cells and NK cells. Details of the amino acid sequence of 4-1BB can be confirmed on websites such as NCBI or UniProt. The primary accession number of 4-1BB listed in UniProt is, for example, Q07011. The amino acid sequence of human 4-1BB is, for example, SEQ ID NO: 62. 4-1BB includes, for example, 4-1BB derived from humans or monkeys.
  • the 4-1BB binding domain comprises, for example, a polypeptide having binding affinity to 4-1BB.
  • the 4-1BB binding domain may comprise, for example, an amino acid sequence in a ligand for 4-1BB or an anti-4-1BB antibody.
  • the 4-1BB binding domain may comprise, for example, a region or domain in a ligand for 4-1BB or an anti-4-1BB antibody having binding affinity to 4-1BB, or a region determining binding affinity to 4-1BB.
  • the region in the ligand for 4-1BB having binding affinity to 4-1BB may be, for example, an extracellular domain.
  • the region in the ligand for 4-1BB having binding affinity to 4-1BB may comprise, for example, the amino acid sequence shown in SEQ ID NO: 39.
  • the ligand for 4-1BB may comprise, for example, 4-1BBL.
  • the 4-1BB-binding domain may, for example, comprise, as an amino acid sequence derived from a ligand for 4-1BB, (i) the amino acid sequence shown in SEQ ID NO: 39, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence shown in SEQ ID NO: 39, or (iii) an amino acid sequence having deletion, substitution, insertion or addition of up to several amino acids to the amino acid sequence shown in SEQ ID NO: 39.
  • the amino acid sequence of the ligand for 4-1BB may, for example, comprise, as an amino acid sequence derived from a ligand for 4-1BB, (i) the amino acid sequence shown in SEQ ID NO: 40, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence shown in SEQ ID NO: 40, or (iii) an amino acid sequence having deletion, substitution, insertion or addition of one to several amino acids to the amino acid sequence shown in SEQ ID NO: 40.
  • the 4-1BB-binding domain may, for example, comprise a trimer of a polypeptide comprising an amino acid sequence derived from a ligand for 4-1BB.
  • the ligand for 4-1BB may, for example, comprise 4-1BBL.
  • the region in the anti-4-1BB antibody that determines the binding ability to 4-1BB may include, for example, the amino acid sequence of heavy chain CDR1 to 3 and light chain CDR1 to 3.
  • the region in the anti-4-1BB antibody that has the binding ability to 4-1BB may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the 4-1BB-binding domain may include, for example, the amino acid sequence of heavy chain CDR1 to 3 and light chain CDR1 to 3 as an amino acid sequence derived from the anti-4-1BB antibody.
  • the 4-1BB-binding domain may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from the anti-4-1BB antibody.
  • the 4-1BB-binding domain may contain, for example, an amino acid sequence derived from an anti-4-1BB antibody, such as (i) an amino acid sequence of the variable region of an anti-4-1BB antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the 4-1BB-binding domain includes a 4-1BB-binding domain capable of activating immune cells (e.g., T cells).
  • the above-mentioned anti-4-1BB antibody may be an agonist antibody.
  • the above anti-4-1BB antibodies can be, for example, anti-4-1BB antibodies described in the literature or commercially available (e.g., Bartkowiak et al., Front Oncol. 2015 Jun 8;5:117 (e.g., ⁇ 4-1BB (PF-05082566) or Urelumab), WO/2000/029445 (e.g., Hz4B4-1) or Shen et al., Am J Cancer Res. 2023 Jul 15;13(7):3246-3256. eCollection 2023., etc.).
  • the GITR includes a protein also known as CD357. Details of the amino acid sequence of GITR can be found on websites such as NCBI or UniProt. The primary accession number of GITR listed in UniProt is, for example, Q9Y5U5. GITR includes, for example, GITR derived from human or monkey.
  • the GITR binding domain comprises, for example, a polypeptide having binding affinity to GITR.
  • the GITR binding domain may comprise, for example, an amino acid sequence in a ligand for GITR or an anti-GITR antibody.
  • the GITR binding domain may comprise, for example, a region or domain having binding affinity to GITR, or a region determining binding affinity to GITR, in a ligand for GITR or an anti-GITR antibody.
  • the region having binding affinity to GITR in a ligand for GITR may be, for example, an extracellular domain.
  • the ligand for GITR may comprise, for example, GITRL (Q9UNG2, UniProt Primary accession number).
  • the GITR binding domain may comprise, for example, an amino acid sequence derived from a ligand for GITR, (i) an amino acid sequence of a ligand for GITR or its extracellular domain, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions or additions to the amino acid sequence.
  • the region in the anti-GITR antibody that determines the binding ability to GITR may include, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region in the anti-GITR antibody that has the binding ability to GITR may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the GITR-binding domain may include, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from the anti-GITR antibody.
  • the GITR-binding domain may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from the anti-GITR antibody.
  • the GITR-binding domain may include, for example, the amino acid sequence derived from the anti-GITR antibody, (i) the amino acid sequence of the variable region of the anti-GITR antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the GITR binding domain includes a GITR binding domain capable of activating immune cells (e.g., T cells).
  • the above anti-GITR antibody may be an agonist antibody.
  • the above anti-GITR antibody may be, for example, an anti-GITR antibody described in the literature or a commercially available anti-GITR antibody (e.g., Knee et al., Eur J Cancer. 2016 Nov;67:1-10. or Schaer et al., Curr Opin Investig Drugs., etc.).
  • the CD27 includes a protein also known as TNFRSF7. Details of the amino acid sequence of CD27 can be found on websites such as NCBI or UniProt. The primary accession number of CD27 listed in UniProt is, for example, P26842. CD27 includes, for example, CD27 derived from human or monkey.
  • the CD27-binding domain comprises, for example, a polypeptide having binding affinity to CD27.
  • the CD27-binding domain may comprise, for example, an amino acid sequence in a ligand for CD27 or an anti-CD27 antibody.
  • the CD27-binding domain may comprise, for example, a region or domain having binding affinity to CD27, or a region determining binding affinity to CD27, in a ligand for CD27 or an anti-CD27 antibody.
  • the region having binding affinity to CD27 in a ligand for CD27 may be, for example, an extracellular domain.
  • the ligand for CD27 may comprise, for example, CD27L (P32970, UniProt Primary accession number).
  • the CD27-binding domain may comprise, for example, an amino acid sequence derived from a ligand for CD27, (i) an amino acid sequence of a ligand for CD27 or its extracellular domain, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions or additions to the amino acid sequence.
  • the region determining the binding ability to CD27 in the anti-CD27 antibody may include, for example, the amino acid sequence of the heavy chain CDR1-3 and the light chain CDR1-3.
  • the region having the binding ability to CD27 in the anti-CD27 antibody may include, for example, the amino acid sequence of the variable region (including, for example, the heavy chain variable region or the light chain variable region).
  • the CD27-binding domain may include, for example, the amino acid sequence of the heavy chain CDR1-3 and the light chain CDR1-3 as an amino acid sequence derived from the anti-CD27 antibody.
  • the CD27-binding domain may include, for example, the amino acid sequence of the variable region (including, for example, the heavy chain variable region or the light chain variable region; the same applies below) as an amino acid sequence derived from the anti-CD27 antibody.
  • the CD27-binding domain may include, for example, the amino acid sequence derived from the anti-CD27 antibody, (i) the amino acid sequence of the variable region of the anti-CD27 antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the CD27 binding domain includes a CD27 binding domain capable of activating immune cells (e.g., T cells).
  • the above anti-GITR antibody may be an agonist antibody.
  • the above anti-CD27 antibody may be, for example, an anti-CD27 antibody described in the literature or a commercially available anti-CD27 antibody (e.g., Sanmamed et al., Semin Oncol. 2015 Aug;42(4):640-55. or Vogel et al., Eur J Immunol. 2022 Oct;52(10):1620-1629., etc.).
  • the CD40 includes a protein also known as TNFRSF5. Details of the amino acid sequence of CD40 can be found on websites such as NCBI or UniProt. The primary accession number of CD40 listed in UniProt is, for example, P25942. CD40 includes, for example, CD40 derived from human or monkey.
  • the CD40 binding domain comprises, for example, a polypeptide having binding affinity to CD40.
  • the CD40 binding domain may comprise, for example, an amino acid sequence in a ligand for CD40 or an anti-CD40 antibody.
  • the CD40 binding domain may comprise, for example, a region or domain having binding affinity to CD40, or a region determining binding affinity to CD40, in a ligand for CD40 or an anti-CD40 antibody.
  • the region having binding affinity to CD40 in a ligand for CD40 may be, for example, an extracellular domain.
  • the ligand for CD40 may comprise, for example, CD40L (P29965, UniProt Primary accession number).
  • the CD40 binding domain may comprise, for example, an amino acid sequence derived from a ligand for CD40, (i) an amino acid sequence of a ligand for CD40 or its extracellular domain, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions or additions to the amino acid sequence.
  • the region determining the binding ability to CD40 in an anti-CD40 antibody may include, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region having the binding ability to CD40 in an anti-CD40 antibody may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the CD40-binding domain may include, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-CD40 antibody.
  • the CD40-binding domain may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-CD40 antibody.
  • the CD40-binding domain may include, for example, the amino acid sequence derived from an anti-CD40 antibody, (i) the amino acid sequence of the variable region of an anti-CD40 antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the CD40 binding domain includes a CD40 binding domain capable of activating immune cells (e.g., T cells).
  • the above anti-GITR antibody may be an agonist antibody.
  • the above anti-CD40 antibody may be, for example, an anti-CD40 antibody described in the literature or a commercially available anti-CD40 antibody (e.g., Lang et al., Int J Mol Sci. 2022 Oct 25;23(21):12869. or Hassan et al., Immunopharmacol Immunotoxicol. 2014 Apr;36(2):96-104., etc.).
  • the NKp30 includes a protein also known as CD337. Details of the amino acid sequence of NKp30 can be found on websites such as NCBI or UniProt. The primary accession number of NKp30 listed in UniProt is, for example, O14931. NKp30 includes, for example, NKp30 derived from humans or monkeys.
  • the NKp30-binding domain comprises, for example, a polypeptide having binding affinity to NKp30.
  • the NKp30-binding domain may comprise, for example, an amino acid sequence in a ligand for NKp30 or an anti-NKp30 antibody.
  • the NKp30-binding domain may comprise, for example, a region or domain in a ligand for NKp30 or an anti-NKp30 antibody that has binding affinity to NKp30, or a region that determines binding to NKp30.
  • the region in a ligand for NKp30 that has binding affinity to NKp30 may be, for example, an extracellular domain.
  • the ligand for NKp30 may comprise, for example, B7-H6 (Q68D85, UniProt Primary accession number).
  • the NKp30-binding domain may, for example, comprise, as an amino acid sequence derived from a ligand for NKp30, (i) the amino acid sequence of a ligand for NKp30 or its extracellular domain, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the region determining the binding ability to NKp30 in an anti-NKp30 antibody may, for example, comprise the amino acid sequences of heavy chain CDR1-3 and light chain CDR1-3.
  • the region having the binding ability to NKp30 in an anti-NKp30 antibody may, for example, comprise the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the NKp30-binding domain may, for example, comprise the amino acid sequences of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-NKp30 antibody.
  • the NKp30-binding domain may comprise, for example, an amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-NKp30 antibody.
  • the NKp30-binding domain may comprise, for example, an amino acid sequence derived from an anti-NKp30 antibody, (i) an amino acid sequence of a variable region of an anti-NKp30 antibody, (ii) an amino acid sequence having 90% or more homology to that amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to that amino acid sequence.
  • the NKp30-binding domain comprises an NKp30-binding domain capable of activating immune cells (for example, T cells).
  • the above anti-GITR antibody may be an agonist antibody.
  • the above anti-NKp30 antibody can be, for example, an anti-NKp30 antibody described in the literature or a commercially available anti-NKp30 antibody (e.g., Zou et al., PLoS One. 2015 Aug 4;10(8):e0134568. or Queiroz t al., BMC Infect Dis. 2019 May 17;19(1):433., etc.).
  • the TIM-3 includes a protein also known as CD366. Details of the amino acid sequence of TIM-3 can be found on websites such as NCBI or UniProt. The primary accession number of TIM-3 listed in UniProt is, for example, Q8TDQ0. TIM-3 includes, for example, TIM-3 derived from humans or monkeys.
  • the TIM-3 binding domain comprises, for example, a polypeptide having binding affinity to TIM-3.
  • the TIM-3 binding domain may comprise, for example, an amino acid sequence in an anti-TIM-3 antibody.
  • the TIM-3 binding domain may comprise, for example, a region or domain in an anti-TIM-3 antibody having binding affinity to TIM-3, or in particular a region determining binding affinity to TIM-3.
  • the region determining binding affinity to TIM-3 in an anti-TIM-3 antibody may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region in an anti-TIM-3 antibody having binding affinity to TIM-3 may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the TIM-3 binding domain may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-TIM-3 antibody.
  • the TIM-3-binding domain may comprise, for example, an amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-TIM-3 antibody.
  • the TIM-3-binding domain may comprise, for example, an amino acid sequence derived from an anti-TIM-3 antibody, (i) an amino acid sequence of a variable region of an anti-TIM-3 antibody, (ii) an amino acid sequence having 90% or more homology to that amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions or additions to that amino acid sequence.
  • the TIM-3-binding domain comprises a TIM-3-binding domain capable of activating immune cells (for example, T cells).
  • the above anti-TIM-3 antibody may be an antagonist antibody.
  • the above anti-TIM-3 antibody can be, for example, an anti-TIM-3 antibody described in the literature or a commercially available anti-TIM-3 antibody (e.g., Bewersdorf et al., Genes Dev. 2022 Mar 1;36(5-6):259-277. or Bailly, Acta Trop. 2023 Feb;238:106792., etc.).
  • the LAG-3 includes a protein also known as CD223. Details of the amino acid sequence of LAG-3 can be found on websites such as NCBI or UniProt. The primary accession number of LAG-3 listed in UniProt is, for example, P18627. LAG-3 includes, for example, LAG-3 derived from humans or monkeys.
  • the LAG-3 binding domain comprises, for example, a polypeptide having binding affinity to LAG-3.
  • the LAG-3 binding domain may comprise, for example, an amino acid sequence in an anti-LAG-3 antibody.
  • the LAG-3 binding domain may comprise, for example, a region or domain in an anti-LAG-3 antibody having binding affinity to LAG-3, or a region that determines binding affinity to LAG-3.
  • the region in an anti-LAG-3 antibody that determines binding affinity to LAG-3 may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region in an anti-LAG-3 antibody that has binding affinity to LAG-3 may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the LAG-3 binding domain may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-LAG-3 antibody.
  • the LAG-3 binding domain may comprise, for example, an amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-LAG-3 antibody.
  • the LAG-3 binding domain may comprise, for example, an amino acid sequence derived from an anti-LAG-3 antibody, (i) an amino acid sequence of a variable region of an anti-LAG-3 antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions or additions to the amino acid sequence.
  • the LAG-3 binding domain comprises a LAG-3 binding domain capable of activating immune cells (for example, T cells).
  • the above anti-LAG-3 antibody may be an antagonist antibody.
  • the above anti-LAG-3 antibody can be, for example, an anti-LAG-3 antibody described in the literature or a commercially available anti-LAG-3 antibody (e.g., Sauer et al., Int J Mol Sci. 2022 Sep 1;23(17):9958. or Kozlowski et al., Biomedicines. 2022 Nov 5;10(11):2826., etc.).
  • the BTLA includes a protein also known as CD272. Details of the amino acid sequence of BTLA can be found on websites such as NCBI or UniProt. The primary accession number of BTLA listed in UniProt is, for example, Q7Z6A9. BTLA includes, for example, BTLA derived from humans or monkeys.
  • the BTLA-binding domain comprises, for example, a polypeptide that has binding affinity to BTLA.
  • the BTLA-binding domain may comprise, for example, an amino acid sequence in an anti-BTLA antibody.
  • the BTLA-binding domain may comprise, for example, a region or domain in an anti-BTLA antibody that has binding affinity to BTLA, or a region that determines binding affinity to BTLA.
  • the region in an anti-BTLA antibody that determines binding affinity to BTLA may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region in an anti-BTLA antibody that has binding affinity to BTLA may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the BTLA-binding domain may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-BTLA antibody.
  • the BTLA-binding domain may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-BTLA antibody.
  • the BTLA-binding domain may, for example, contain an amino acid sequence derived from an anti-BTLA antibody, such as (i) an amino acid sequence of the variable region of an anti-BTLA antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the BTLA-binding domain includes a BTLA-binding domain capable of activating immune cells (e.g., T cells).
  • the above anti-BTLA antibody may be an antagonist antibody.
  • the above anti-BTLA antibody may be, for example, an anti-BTLA antibody described in the literature or commercially available (e.g., Sordo-Bahamonde et al., Mol Cancer. 2023 Aug 30; 22(1): 142. or Chen et a., J Immunother Cancer. 2019 Nov 21; 7(1): 313., etc.).
  • the CTLA-4 includes a protein also known as CD152. Details of the amino acid sequence of CTLA-4 can be found on websites such as NCBI or UniProt. The primary accession number of CTLA-4 listed in UniProt is, for example, P16410. CTLA-4 includes, for example, human or simian CTLA-4.
  • the CTLA-4 binding domain comprises, for example, a polypeptide having binding affinity to CTLA-4.
  • the CTLA-4 binding domain may comprise, for example, an amino acid sequence in an anti-CTLA-4 antibody.
  • the CTLA-4 binding domain may comprise, for example, a region or domain in an anti-CTLA-4 antibody having binding affinity to CTLA-4, or in particular a region that determines binding affinity to CTLA-4.
  • the region in an anti-CTLA-4 antibody that determines binding affinity to CTLA-4 may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region in an anti-CTLA-4 antibody that has binding affinity to CTLA-4 may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the CTLA-4 binding domain may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-CTLA-4 antibody.
  • the CTLA-4 binding domain may comprise, for example, an amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-CTLA-4 antibody.
  • the CTLA-4 binding domain may comprise, for example, an amino acid sequence derived from an anti-CTLA-4 antibody, (i) an amino acid sequence of a variable region of an anti-CTLA-4 antibody, (ii) an amino acid sequence having 90% or more homology to that amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions or additions to that amino acid sequence.
  • the CTLA-4 binding domain comprises a CTLA-4 binding domain capable of activating immune cells (for example, T cells).
  • the above anti-CTLA-4 antibody may be an antagonist antibody.
  • the above anti-CTLA-4 antibodies can be, for example, anti-CTLA-4 antibodies described in the literature or commercially available (e.g., Seidel et al., Front Oncol. 2018 Mar 28;8:86. or Blank et al., Int Immunol. 2015 Jan;27(1):3-10., etc.).
  • the CD73 includes a protein also known as Ecto-5'-nucleotidase. Details of the amino acid sequence of CD73 can be found on websites such as NCBI or UniProt. The primary accession number of CD73 listed in UniProt is, for example, P21589. CD73 includes, for example, CD73 derived from human or monkey.
  • the CD73 binding domain comprises, for example, a polypeptide having binding affinity to CD73.
  • the CD73 binding domain may comprise, for example, an amino acid sequence in an anti-CD73 antibody.
  • the CD73 binding domain may comprise, for example, a region or domain in an anti-CD73 antibody having binding affinity to CD73, or a region that determines binding affinity to CD73.
  • the region in an anti-CD73 antibody that determines binding affinity to CD73 may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region in an anti-CD73 antibody that has binding affinity to CD73 may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the CD73 binding domain may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-CD73 antibody.
  • the CD73-binding domain may comprise, for example, an amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-CD73 antibody.
  • the CD73-binding domain may comprise, for example, an amino acid sequence derived from an anti-CD73 antibody, (i) an amino acid sequence of a variable region of an anti-CD73 antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the CD73-binding domain comprises a CD73-binding domain capable of activating immune cells (for example, T cells).
  • the above-mentioned anti-CD73 antibody may be an antagonist antibody or a neutralizing antibody.
  • anti-CD73 antibodies can be, for example, anti-CD73 antibodies described in the literature or commercially available (e.g., Kurago et al., Front Immunol. 2023 Jun 26;14:1212209. or Minor et al., Am J Physiol Cell Physiol. 2019 Dec 1;317(6):C1079-C1092., etc.).
  • the CD3 comprises a protein complex that non-covalently associates with the T cell receptor (TCR) and functions as a co-receptor for T cells.
  • CD3 comprises gamma, delta, epsilon, and zeta subunits. Details of the amino acid sequence of CD3 can be found on websites such as NCBI or UniProt. The primary accession number of CD3 listed in UniProt is, for example, P07766.
  • the amino acid sequence of human CD3 epsilon (CD3E) comprises, for example, the amino acid sequence shown in SEQ ID NO: 63.
  • CD3 includes, for example, CD3 derived from a human or monkey.
  • the CD3 binding domain comprises, for example, a polypeptide having binding affinity to CD3.
  • the CD3 binding domain may comprise, for example, an amino acid sequence in an anti-CD3 antibody.
  • the CD3 binding domain may comprise, for example, a region or domain having binding affinity to CD3, or a region determining binding affinity to CD3, in an anti-CD3 antibody.
  • the region determining binding affinity to CD3 in an anti-CD3 antibody may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3.
  • the region having binding affinity to CD3 in an anti-CD3 antibody may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the CD3 binding domain may comprise, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from an anti-CD3 antibody.
  • the CD3 binding domain may comprise, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from an anti-CD3 antibody.
  • the CD3-binding domain may contain, for example, an amino acid sequence derived from an anti-CD3 antibody, such as (i) an amino acid sequence of a variable region of an anti-CD3 antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the CD3-binding domain includes a CD3-binding domain capable of activating immune cells (e.g., T cells).
  • the above anti-CD3 antibody may be an agonist antibody.
  • the anti-CD3 antibody may be, for example, an anti-CD3 antibody described in the literature or commercially available (e.g., Goebeler et al., Leuk Lymphoma. 2016 May;57(5):1021-32.; Sun et al., Sci Transl Med. 2015 May 13;7(287):287ra70.; Pessano et al., EMBO J. 1985 Feb;4(2):337-44. Tokhyo 2018-501297. WO2007042261).
  • the anti-CD3 antibody may be, for example, OKT3, SP34, or an antibody comprising heavy chain CDR1-3 or light chain CDR1-3 thereof.
  • the above anti-CD3 antibody may, for example, have heavy chain CDR1-3 containing the amino acid sequences shown in SEQ ID NOs: 46-48, respectively, and light chain CDR1-3 containing the amino acid sequences shown in SEQ ID NOs: 49-51, respectively.
  • the above anti-CD3 antibody may have a heavy chain variable region containing the amino acid sequence shown in SEQ ID NO: 52, respectively, and a light chain variable region containing the amino acid sequence shown in SEQ ID NO: 53, respectively.
  • the above anti-CD3 antibody may, for example, have heavy chain CDR1-3 containing the amino acid sequences shown in SEQ ID NOs: 70-72, respectively, and light chain CDR1-3 containing the amino acid sequences shown in SEQ ID NOs: 73-75, respectively.
  • the above anti-CD3 antibody may have a heavy chain variable region containing the amino acid sequence shown in SEQ ID NO: 76, respectively, and a light chain variable region containing the amino acid sequence shown in SEQ ID NO: 77, respectively.
  • the TGF ⁇ includes a protein also referred to as transforming growth factor ⁇ .
  • TGF ⁇ includes the isoforms TGF ⁇ -1, TGF ⁇ -2, and TGF ⁇ -3. Details of the amino acid sequence of TGF ⁇ can be confirmed on websites such as NCBI or UniProt. The primary accession numbers of TGF ⁇ listed in UniProt are, for example, P01137, P61812, or P10600 for each isoform.
  • the amino acid sequence of human TGF ⁇ includes, for example, the amino acid sequences shown in SEQ ID NOs: 64 to 66 for each isoform.
  • TGF ⁇ includes, for example, TGF ⁇ derived from a human or monkey.
  • the TGF ⁇ -binding domain comprises, for example, a polypeptide having binding affinity to TGF ⁇ .
  • the TGF ⁇ -binding domain may comprise, for example, an amino acid sequence in a receptor for TGF ⁇ or an anti-TGF ⁇ antibody.
  • the TGF ⁇ -binding domain may comprise, for example, a region or domain having binding affinity to TGF ⁇ , or a region determining binding affinity to TGF ⁇ , in a receptor for TGF ⁇ or an anti-TGF ⁇ antibody.
  • the region having binding affinity to TGF ⁇ in a receptor for TGF ⁇ may be, for example, an extracellular domain (e.g., an amino acid sequence at positions 23-166).
  • the region having binding affinity to TGF ⁇ in a receptor for TGF ⁇ may comprise, for example, the amino acid sequence shown in SEQ ID NO: 54.
  • the receptor for TGF ⁇ may comprise, for example, TGF ⁇ R2 (P37173, UniProt Primary accession number).
  • the TGF ⁇ -binding domain may comprise, for example, an amino acid sequence derived from a receptor for TGF ⁇ , such as (i) the amino acid sequence shown in SEQ ID NO: 54, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence shown in SEQ ID NO: 54, or (iii) an amino acid sequence having deletion, substitution, insertion or addition of up to several amino acids to the amino acid sequence shown in SEQ ID NO: 54.
  • the amino acid sequence of the receptor for TGF ⁇ may comprise, for example, the amino acid sequence shown in SEQ ID NO: 55.
  • the TGF ⁇ -binding domain may comprise, for example, an amino acid sequence derived from a receptor for TGF ⁇ , such as (i) the amino acid sequence shown in SEQ ID NO: 55, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence shown in SEQ ID NO: 55, or (iii) an amino acid sequence having deletion, substitution, insertion or addition of one to several amino acids to the amino acid sequence shown in SEQ ID NO: 55.
  • the region determining the binding ability to TGF ⁇ in the anti-TGF ⁇ antibody may comprise, for example, the amino acid sequences of heavy chain CDR1 to 3 and light chain CDR1 to 3.
  • the region in the anti-TGF ⁇ antibody that has binding ability to TGF ⁇ may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region).
  • the TGF ⁇ -binding domain may include, for example, the amino acid sequence of heavy chain CDR1-3 and light chain CDR1-3 as an amino acid sequence derived from the anti-TGF ⁇ antibody.
  • the TGF ⁇ -binding domain may include, for example, the amino acid sequence of a variable region (including, for example, a heavy chain variable region or a light chain variable region; the same applies below) as an amino acid sequence derived from the anti-TGF ⁇ antibody.
  • the TGF ⁇ -binding domain may include, for example, the amino acid sequence derived from the anti-TGF ⁇ antibody, (i) the amino acid sequence of the variable region of the anti-TGF ⁇ antibody, (ii) an amino acid sequence having 90% or more homology to the amino acid sequence, or (iii) an amino acid sequence having one to several amino acid deletions, substitutions, insertions, or additions to the amino acid sequence.
  • the TGF ⁇ -binding domain includes a TGF ⁇ -binding domain that has the ability to activate immune cells (for example, T cells).
  • the above-mentioned anti-TGF ⁇ antibody may be an agonist antibody.
  • anti-TGF ⁇ antibodies can be, for example, anti-TGF ⁇ antibodies described in the literature or commercially available (e.g., Yi et al., J Hematol Oncol. 2022 Oct 8;15(1):142. or Niu et al., J Hematol Oncol. 2023 Aug 12;16(1):94., etc.).
  • the multispecific antigen-binding molecule may be a humanized multispecific antigen-binding molecule.
  • the humanized multispecific antigen-binding molecule may, for example, have amino acid sequences other than the CDRs derived from a human immunoglobulin.
  • the humanized multispecific antigen-binding molecule may, for example, have one or more CDRs derived from a non-human species, framework regions derived from a human immunoglobulin, and optionally constant regions derived from a human immunoglobulin, and may include a domain that binds to a desired antigen.
  • the humanization of the multispecific antigen-binding molecule may be carried out, for example, by a procedure such as that described in Example 3.1 below.
  • Various other techniques known in the art may also be used (e.g., Safdari et al., Biotechnol Genet Eng Rev. 2013;29:175-86.).
  • the multispecific antigen-binding molecule may, for example, comprise an Fc region.
  • the Fc region may, for example, be an IgG, IgA, IgM, IgE or IgD type Fc region.
  • IgG includes, for example, IgG1, IgG2, IgG3 or IgG4.
  • the Fc region may, for example, have a knob mutation and a hole mutation in separate chains.
  • the Fc region may, for example, have an L234A mutation and an L235A mutation.
  • the multispecific antigen-binding molecule may be, for example, a T cell engager.
  • the multispecific antigen-binding molecule may exert an anti-tumor effect, for example, by redirecting T cells.
  • the multispecific antigen-binding molecule may have a first arm and a second arm.
  • the first arm may, for example, have the first binding domain.
  • the second arm may, for example, have the second binding domain.
  • the multispecific antigen-binding molecule may include a first binding domain and a second binding domain, and may further include a third binding domain or a fourth binding domain.
  • the first binding domain may be located on the N-terminus side of the Fc region in the multispecific antigen-binding molecule.
  • the second binding domain may be located on the N-terminus side or C-terminus side of the Fc region in the multispecific antigen-binding molecule.
  • the third binding domain and the fourth binding domain may be located on the C-terminus side of the Fc region in the multispecific antigen-binding molecule.
  • the first binding domain and the second binding domain, or the polypeptide including the first binding domain and the polypeptide including the second binding domain may be linked via a linker.
  • the linker includes a compound for crosslinking two or more entities, which is not directly involved in binding to an antigen.
  • the linker includes, for example, a peptide linker.
  • the peptide linker may be a GS linker or a G linker.
  • the GS linker includes, for example, a linker composed of glycine (G) and serine (S) residues.
  • the GS linker may include, for example, a GGGGS motif (SEQ ID NO: 67).
  • the GS linker may be, for example, a linker represented by (GGGGS)n (n represents a number, and may be, for example, 1, 2, 3, 4, 5, 6, 7, or 8, or may be equal to or greater than any of these values, or may be within a range between any two of these values).
  • the G linker may be, for example, a linker represented by Gn (n represents a number, and may be, for example, 3, 4, 5, 6, 7, or 8, or may be any one of these values or more, or may be within a range between any two of these values).
  • the number of amino acid residues contained in the peptide linker may be, for example, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, or 40, or may be any one of these values or more, or may be within a range between any two of these values.
  • a peptide, a constant region, or an Fc region may be used as a linker.
  • the multispecific antigen-binding molecule may have a form in which a first arm including a first binding domain-peptide linker in the order from the N-terminus to the C-terminus, and a second arm including a second binding domain-peptide linker-constant region in the order from the N-terminus to the C-terminus are linked with an Fc region in between.
  • a peptide linker may be further interposed between any of these.
  • the multispecific antigen-binding molecule may bind to human CD39 on a cell membrane with a K D (M) of, for example, 5.0 ⁇ 10 ⁇ 7 or less.
  • K D (M) may be a value calculated from the results obtained by flow cytometry.
  • K D (M) may be a value measured by surface plasmon resonance (SPR).
  • the multispecific antigen-binding molecule may bind to isolated human CD39 with a K D (M) of, for example, 1.0 ⁇ 10 ⁇ 8 or less. This value may be, for example, 1.0 ⁇ 10 ⁇ 8 , 5.0 ⁇ 10 ⁇ 9 , 1.0 ⁇ 10 ⁇ 9 , 5.0 ⁇ 10 ⁇ 10 , or 1.0 ⁇ 10 ⁇ 10 , or may be less than or equal to any of these values, or within a range of any two of these values.
  • the multispecific antigen-binding molecule may bind to an antigen other than isolated human CD39 (e.g., an immune cell surface antigen or an anti-inflammatory cytokine) with a K D (M) of , for example, 5.0 ⁇ 10 ⁇ 6 or less.
  • K D K D
  • This value may be, for example, 5.0 ⁇ 10 ⁇ 6 , 1.0 ⁇ 10 ⁇ 6 , 5.0 ⁇ 10 ⁇ 7 , 1.0 ⁇ 10 ⁇ 7 , 5.0 ⁇ 10 ⁇ 8 , 1.0 ⁇ 10 ⁇ 8 , 5.0 ⁇ 10 ⁇ 9 , or 1.0 ⁇ 10 ⁇ 9 , or less than or equal to any of these values, or within a range of any two of these values.
  • the multispecific antigen-binding molecule includes, for example, a multispecific monoclonal antibody.
  • the multispecific antigen-binding molecule may be a multispecific antigen-binding molecule that has binding affinity to wild-type or mutant forms of CD39.
  • Mutant forms of CD39 include those resulting from differences in DNA sequences between individuals, such as SNPs.
  • the multispecific antigen-binding molecule may be in an IgG format, an IgG-like format (e.g., a format having an Fc region), or a fragment-based format (e.g., a format free of the Fc region) (see, e.g., Elshiaty et al., Int J Mol Sci. 2021 May 26;22(11):5632.; Nie et al., Antib Ther. 2020 Jan;3(1):18-62; Kang et al., Front Immunol. 2022 Oct 20;13:1020003.; or Brinkmann et al., MAbs. 2017 Feb/Mar;9(2):182-212.).
  • IgG format an IgG-like format
  • a fragment-based format e.g., a format free of the Fc region
  • the IgG format includes, for example, a format in which, in an IgG-like molecule having two arms and an Fc region, the first arm includes a Fab region that recognizes a first antigen, and the second arm includes a Fab region that recognizes a second antigen.
  • the first antigen and the second antigen are different types of antigens.
  • the IgG-like format includes, for example, (i) a format in which, in an IgG-like molecule having two arms and an Fc region, the first arm includes a polypeptide (e.g., Fab or scFv) including a variable region (e.g., a heavy chain variable region or a light chain variable region) that recognizes a first antigen, and the second arm includes a polypeptide (e.g., Fab or scFv) including a variable region (e.g., a heavy chain variable region or a light chain variable region) that recognizes a second antigen, and when one arm is Fab, the other arm is a format other than Fab; and (ii) a format in which, in an IgG-like molecule having an Fc region, the Fc region includes a bispecific diabody, scDb (shin (iii) a format in which an IgG-like molecule having two arms and an Fc region comprises a polypeptid
  • Fragment-based formats include, for example, (i) a format that does not have an Fc region and includes a polypeptide that includes a variable region (e.g., a heavy chain variable region or a light chain variable region) that recognizes a first antigen and a polypeptide that includes a variable region (e.g., a heavy chain variable region or a light chain variable region) that recognizes a second antigen, where the polypeptides are linked by a linker or are conjugated, or (ii) a format that does not have an Fc region and includes a polypeptide that includes a variable region (e.g., a heavy chain variable region or a light chain variable region) that recognizes a first antigen and a polypeptide that includes a ligand or receptor for a second antigen or an antigen-binding fragment thereof, where the polypeptides are linked by a linker or are conjugated.
  • a variable region e.g., a heavy chain variable region or a light chain
  • the multispecific antigen-binding molecule may be in the format of scFv-Lig-Fc, Fab-Lig-Fc, scFv-Fab-Fc, scFv-scFv-Fc, Fab-Fab-Fc, diabody-Lig-Fc, diabody-Fab-Fc, or diabody-diabody-Fc (showing an intervening sequence between the first arm-second arm-arm).
  • Lig is a polypeptide comprising a ligand or receptor for an antigen or an antigen-binding fragment thereof.
  • the multispecific antigen-binding molecule may be in the format of, for example, a bispecific diabody, a single-chain diabody (scDb), or a tandem scFv.
  • the multispecific antigen-binding molecule may be in the format of, for example, a first chain comprising a first binding domain, an optional linker, and an Fc region in the order from the N-terminus to the C-terminus, and a second chain comprising a second binding domain, an optional linker, a constant region, and an Fc region in the order from the N-terminus to the C-terminus, and the first chain and the second chain are linked by a disulfide bond.
  • the constant region may be in the form of, for example, a first constant region (e.g., a heavy chain constant region (e.g., CH1)) and a second constant region (e.g., a light chain constant region (e.g., C ⁇ )) complexed (e.g., linked by a disulfide bond).
  • the second binding domain may, for example, form a trimer (first to third chains), in which the first and second chains are linked by a linker, and one of the first and second chains may be linked to the first constant region via a linker.
  • the third chain may, for example, be linked to the second constant region via a linker.
  • Multispecific antigen-binding molecules can be produced, for example, using the method described in Wang et al., Antibodies (Basel). 2019 Aug 2;8(3):43.
  • the multispecific antigen-binding molecule may not include a molecule that targets or has binding affinity to TIM-3 (T-cell immunoglobulin and mucin domain 3), if specified. In one embodiment of the present invention, the multispecific antigen-binding molecule may not include a molecule that inhibits the function of TIM-3, if specified. In one embodiment of the present invention, the immune cell surface antigen may not include TIM-3, if specified.
  • the origin of TIM-3 is not limited, and TIM-3 includes, for example, TIM-3 derived from a mammal (e.g., human or monkey).
  • a multispecific polypeptide comprising a CD39-binding domain having binding ability to CD39, the CD39-binding domain comprising any one of the CDR sets (a) to (d) above.
  • a multispecific complex comprising a CD39-binding domain having binding ability to CD39, the CD39-binding domain comprising any one of the CDR sets (a) to (d) above. Any of the embodiments described above regarding the multispecific antigen-binding molecule can be applied to this multispecific complex.
  • an antigen-binding molecule having multiple antigen-binding domains, one of which is a CD39-binding domain having binding ability to CD39, and the CD39-binding domain has any one of the CDR sets (a) to (d). Any of the embodiments described above regarding the multispecific antigen-binding molecule can be applied to this antigen-binding molecule.
  • a polypeptide comprising any one of the CDR sets (a) to (d).
  • This polypeptide may be, for example, a multispecific antigen-binding molecule.
  • This polypeptide may be, for example, a multispecific antibody or a multispecific fusion protein.
  • This polypeptide may be, for example, an antibody.
  • This polypeptide may be, for example, an scFv or Fab. Any of the embodiments described above regarding the multispecific antigen-binding molecule may be applicable to this polypeptide.
  • a polypeptide or complex that includes a first binding domain and a second binding domain.
  • the first binding domain includes, for example, a domain that includes any of the CDR sets (a) to (d) above. Any of the embodiments described above regarding the multispecific antigen-binding molecule can be applied to this polypeptide or complex.
  • a multispecific antigen-binding molecule comprising a first polypeptide and a second polypeptide.
  • the first polypeptide comprises, for example, a polypeptide comprising any one of the CDR sets (a) to (d) above.
  • a linker may be present between the first binding polypeptide and the second binding polypeptide.
  • the first binding polypeptide and the second binding polypeptide may be linked via an Fc region.
  • a multispecific antigen-binding molecule comprising an anti-CD39 antibody comprising any one of the CDR sets (a) to (d) above. Any of the embodiments described above regarding the multispecific antigen-binding molecule can be applied to this multispecific antigen-binding molecule.
  • an antigen-binding fragment of the multispecific antigen-binding molecule is provided.
  • This antigen-binding fragment may have binding affinity to CD39 and binding affinity to an immune cell surface antigen or an anti-inflammatory cytokine.
  • a domain comprising any one of the CDR sets (a) to (d).
  • This domain may be a CD39-binding domain having binding ability to CD39.
  • This CD39-binding domain may be a CD39-binding domain used as a component of or incorporated into a multispecific antigen-binding molecule. Any of the embodiments described above regarding the CD39-binding domain may be applied to this domain.
  • a multispecific antigen-binding molecule (hereinafter sometimes referred to as a reference molecule) that comprises a CD39-binding domain according to an embodiment of the present invention (e.g., a CD39-binding domain having any of the CDR sets (a) to (d) above) and that competes for binding to CD39.
  • Competition includes inhibition of binding of another multispecific antigen-binding molecule to an antigen by binding to the same antigen by a multispecific antigen-binding molecule.
  • Competitive multispecific antigen-binding molecules can be identified, for example, by competitive binding assays.
  • Competitive binding assays include, for example, competitive ELISA and competitive FACS analysis (see, for example, Zhou et al., J Gen Virol. 2008 Feb;89(Pt 2):500-508). Binding may be measured, for example, by surface plasmon resonance.
  • the competitive binding assay may include, for example, a step of coating an antigen on a microplate, adding a test polyspecific antigen-binding molecule (hereinafter, sometimes referred to as a test molecule) and incubating to form a bond between the antigen and the test molecule, a step of adding a labeled reference molecule to the well, incubating and washing, or a step of quantifying the amount of binding of the labeled reference molecule to the antigen.
  • a test polyspecific antigen-binding molecule hereinafter, sometimes referred to as a test molecule
  • the binding amount of the biotinylated reference antibody may be detected by measuring absorbance at a measurement wavelength of 450 nm using HRP-conjugated streptavidin and 3,3',5,5'-tetramethylbenzidine.
  • the percentage of reduction in the binding amount of the labeled reference molecule compared to the case where the test molecule is not added or the negative control is added may be evaluated as the inhibition rate.
  • the inhibition of the competing antibody against the reference molecule includes 20, 30, 40, 50, 60, 70, 80, 90% or more, or 100% inhibition. This inhibition is preferably 40% or more, particularly preferably 50% or more.
  • the competing multispecific antigen-binding molecule may have binding affinity for the epitope to which the reference molecule binds.
  • one embodiment of the present invention provides a polypeptide comprising any one of the CDR sets (a) to (d) above.
  • the polypeptide may be a CD39-binding domain, a multispecific antigen-binding molecule, a variable region, or an antibody.
  • a composition used for delivering immune cells to the vicinity of malignant tumor cells comprising a polypeptide comprising any one of the CDR sets (a) to (d) above.
  • a method for delivering immune cells to the vicinity of malignant tumor cells comprising contacting a polypeptide comprising any one of the CDR sets (a) to (d) above with malignant tumor cells and immune cells.
  • composition used for crosslinking malignant tumor cells and immune cells comprising a polypeptide comprising any one of the CDR sets (a) to (d) above.
  • method for crosslinking malignant tumor cells and immune cells comprising contacting a polypeptide comprising any one of the CDR sets (a) to (d) above with the malignant tumor cells and immune cells.
  • a composition comprising a multispecific antigen-binding molecule, in which 90 or 95% or more of the multispecific antigen-binding molecules in the composition have the same amino acid sequence as the multispecific antigen-binding molecule described above (e.g., having any of the CDR sets (a) to (d) above).
  • a composition comprising a multispecific antigen-binding molecule, in which 90 or 95% or more of the molecules comprising an antigen-binding domain in the composition have the same amino acid sequence as the multispecific antigen-binding molecule described above (e.g., having any of the CDR sets (a) to (d) above).
  • a method for enhancing the ability of a composition to inhibit the proliferation of malignant tumor cells comprising the step of increasing the proportion of the above-mentioned CD39-binding domain or multispecific antigen-binding molecule (e.g., having any of the above-mentioned CDR sets (a) to (d)) in the composition.
  • a CD39 binding domain, a multispecific antigen-binding molecule, or an anti-CD39 antibody having the amino acid sequences of heavy and light chain CDRs 1-3, or the amino acid sequences of the variable regions, as defined by the Kabat definition (Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) within the amino acid sequence of P4, T86, I67, Tre291, P4_sc, T86_sc, I67_sc, Tre291_sc, HuP4_IB, or HuT86_IF.
  • the CDRs are defined by the Kabat definition unless otherwise specified.
  • a polypeptide that includes a CD39-binding domain and an immune cell surface antigen-binding domain.
  • This polypeptide may be, for example, a multispecific antigen-binding molecule. Possible embodiments of this multispecific antigen-binding molecule are as described above.
  • the CD39-binding domain may include an amino acid sequence in an anti-CD39 antibody (e.g., an amino acid sequence of a CDR or a variable region), and the immune cell surface antigen-binding domain may include an amino acid sequence in a ligand for an immune cell surface antigen or an amino acid sequence in an antibody for an immune cell surface antigen (e.g., an amino acid sequence of a CDR or a variable region).
  • an anti-CD39 antibody e.g., an amino acid sequence of a CDR or a variable region
  • the immune cell surface antigen-binding domain may include an amino acid sequence in a ligand for an immune cell surface antigen or an amino acid sequence in an antibody for an immune cell surface antigen (e.g., an amino acid sequence of a CDR or a variable region).
  • a polypeptide that includes a CD39-binding domain and a 4-1BB-binding domain.
  • This polypeptide may be, for example, a multispecific antigen-binding molecule. Possible embodiments of this multispecific antigen-binding molecule are as described above.
  • the CD39-binding domain may include an amino acid sequence in an anti-CD39 antibody (e.g., an amino acid sequence of a CDR or a variable region)
  • the 4-1BB-binding domain may include an amino acid sequence in a ligand for 4-1BB or an amino acid sequence in an anti-4-1BB antibody (e.g., an amino acid sequence of a CDR or a variable region).
  • a polypeptide that includes a CD39-binding domain and a CD3-binding domain.
  • This polypeptide may be, for example, a multispecific antigen-binding molecule. Possible embodiments of this multispecific antigen-binding molecule are as described above.
  • the CD39-binding domain may include an amino acid sequence in an anti-CD39 antibody (e.g., an amino acid sequence of a CDR or a variable region)
  • the CD3-binding domain may include an amino acid sequence in a ligand for CD3 or an amino acid sequence in an anti-CD3 antibody (e.g., an amino acid sequence of a CDR or a variable region).
  • the CDR complementarity determining region
  • the CDR is a region that forms a binding site with an antigen.
  • the CDR is located on the Fv (variable region: including the heavy chain variable region (VH) and the light chain variable region (VL)) of an antibody.
  • CDRs are CDR1, CDR2, and CDR3, each consisting of about 3 to 30 amino acid residues, and are present in the heavy chain and the light chain, respectively. It is known that the CDR of the heavy chain particularly contributes to the binding of the antibody to the antigen. Among the CDRs, it is known that CDR3 contributes most to the binding of the antibody to the antigen.
  • the Fv region other than the CDRs is called the framework region, which includes FR1, FR2, FR3, and FR4, and is relatively well conserved among antibodies (e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co.).
  • the bispecific antibody includes an antibody having binding affinity to two different types of antigens.
  • the bispecific antibody may have a CD39 binding domain as a first binding domain.
  • the bispecific antibody may have an immune cell surface antigen binding domain or an anti-inflammatory cytokine binding domain as a second binding domain.
  • the bispecific antibody may have the first binding domain and the second binding domain in a single molecule or in a complexed form. In this case, an intervening sequence (e.g., a linker, an Fc region, or a constant region) may be present between the first binding domain and the second binding domain.
  • the bispecific antibody includes an antibody in which the two binding domains have antibody-derived sequences (e.g., CDRs, variable regions).
  • the bispecific antibody may form any of the formats of the multispecific antigen-binding molecules described above.
  • the bispecific antigen-binding fusion protein includes a fusion protein having binding affinity to two different types of antigens.
  • the bispecific antigen-binding fusion protein may have a CD39-binding domain as a first binding domain.
  • the bispecific antigen-binding fusion protein may have an immune cell surface antigen-binding domain or an anti-inflammatory cytokine-binding domain as a second binding domain.
  • the bispecific antigen-binding fusion protein may have the first binding domain and the second binding domain in a single molecule or in a complexed form. In this case, an intervening sequence (e.g., a linker, an Fc region, or a constant region) may be present between the first binding domain and the second binding domain.
  • an intervening sequence e.g., a linker, an Fc region, or a constant region
  • the bispecific antigen-binding fusion protein includes a fusion protein in which at least one domain (e.g., the second binding domain) does not have an antibody-derived sequence (e.g., a CDR, a variable region).
  • the bispecific antigen-binding fusion protein may have at least one domain (e.g., the second binding domain) that includes a ligand or receptor for an antigen or an antigen-binding fragment thereof.
  • the bispecific antigen-binding fusion protein may form any of the formats of the multispecific antigen-binding molecules described above.
  • the antibody includes a molecule or a group thereof that can specifically bind to a specific epitope on an antigen.
  • the antibody may be a monoclonal antibody.
  • the antibody may exist in various forms, for example, a full-length antibody (an antibody having a Fab region and an Fc region), an Fv antibody, a Fab antibody, an F(ab') 2 antibody, an Fab' antibody, a diabody, a single-chain antibody (e.g., scFv), a dsFv, a scFvFc, a multispecific antibody (e.g., a bispecific antibody), a peptide or polypeptide having antigen-binding ability, a chimeric antibody, a mouse antibody, a humanized antibody, a human antibody, or an equivalent thereof (or an equivalent thereof).
  • the antibody also includes a modified or unmodified antibody.
  • the modified antibody may be an antibody bound to various molecules such as polyethylene glycol.
  • the modified antibody can be obtained by chemically modifying the antibody using a known method.
  • the antibody may also be in the form of a fusion protein.
  • the fusion protein may be an antibody bound to a polypeptide or oligopeptide (e.g., a His tag) at the N- or C-terminus.
  • the form of the fusion protein may be one in which one arm of the antibody is replaced with a polypeptide other than Fab (e.g., a ligand or a receptor).
  • the antibody may be a conjugated antibody (e.g., an antibody-drug complex).
  • the drug may be, for example, a cytotoxic drug or an anticancer drug.
  • Such antibody modifications, fusion proteins, and conjugated antibodies are also included in the form of the antibody.
  • the amino acid sequence, class, or subclass of the antibody may be derived from, for example, a human or a mammal other than a human (e.g., a rat, a mouse, a rabbit, a cow, a monkey, etc.).
  • the antibody may be, for example, an isolated antibody, a purified antibody, or a recombinant antibody.
  • the antibody may be used, for example, in vitro or in vivo.
  • the monoclonal antibody includes an antibody in which each antibody constituting the population reacts with substantially the same epitope.
  • one antibody may react with two epitopes.
  • the antibody may be an antibody in which each antibody constituting the population is substantially identical (naturally occurring mutations are allowed).
  • the method for producing the monoclonal antibody but the antibody may be produced, for example, by a method similar to the hybridoma method described in "Kohler G, Milstein C., Nature. 1975 Aug 7;256(5517):495-497.”
  • the monoclonal antibody may be produced by a method similar to the recombinant method described in U.S. Pat.
  • monoclonal antibodies may be isolated from phage antibody libraries using techniques similar to those described in "Clackson et al., Nature. 1991 Aug 15;352(6336):624-628.” or "Marks et al., J Mol Biol. 1991 Dec 5;222(3):581-597.” or may be produced by the methods described in "Protein Experiment Handbook, Yodosha (2003):92-96.”
  • the chimeric antibody is, for example, a combination of an antibody variable region and an antibody constant region between different organisms, and can be constructed by recombinant gene technology.
  • Examples include chimeric antibodies derived from non-human mammals and humans (e.g., mouse-human chimeric antibodies).
  • Mouse-human chimeric antibodies can be prepared, for example, by the method described in "Roguska et al., Proc Natl Acad Sci U S A.
  • mouse-human chimeric antibodies are, for example, to link mouse leader sequences and variable region sequences present in cloned cDNA to sequences encoding human antibody constant regions already present in a mammalian cell expression vector.
  • mouse leader sequences and variable region sequences present in cloned cDNA may be linked to sequences encoding human antibody constant regions, which may then be linked to a mammalian cell expression vector.
  • the fragment of the human antibody constant region can be any human antibody H chain constant region or human antibody L chain constant region, for example, C ⁇ 1, C ⁇ 2, C ⁇ 3, or C ⁇ 4 for the human H chain, and C ⁇ or C ⁇ for the L chain.
  • the humanized antibody includes, for example, an antibody that has one or more CDRs from a non-human species, a framework region from a human immunoglobulin, and a constant region from a human immunoglobulin, and that binds to a desired antigen.
  • an antibody that has one or more CDRs from a non-human species e.g., a human immunoglobulin, and a constant region from a human immunoglobulin, and that binds to a desired antigen.
  • Various other techniques known in the art may also be used (e.g., Safdari et al., Biotechnol Genet Eng Rev. 2013;29:175-86.).
  • the scFv single chain Fv
  • the scFv includes an antibody in which a heavy chain variable region (VH) and a light chain variable region (VL) are linked via an appropriate peptide linker.
  • the scFv can be produced, for example, by obtaining cDNA encoding VH and VL (e.g., VH and VL containing any of the CDR sets (a) to (d) above), constructing a polynucleotide encoding VH-peptide linker-VL, incorporating the polynucleotide into a vector, and using an expression cell.
  • the Fab includes an antibody in which the heavy chain, excluding the Fc region, and the light chain are linked via a disulfide bond.
  • the Fab can be produced, for example, using a vector encoding the VH-CH1 region and the light chain.
  • the diabody includes an antibody in the form of dimerized scFv and having bivalent antigen-binding activity.
  • the bivalent antigen-binding activities can be the same, or one can have a different antigen-binding activity.
  • a diabody can be produced by constructing a polynucleotide encoding an scFv such that the amino acid sequence of the peptide linker is 8 to 4 residues long (preferably 5 residues), incorporating the resulting polynucleotide into a vector, and using an expression cell.
  • a bispecific diabody can be produced by combining the VH and VL DNA of two different scFvs and expressing the scFv.
  • the scFvFc includes an antibody in a form in which the scFv and the Fc region are linked via a suitable linker.
  • the polynucleotides encoding the scFv, the linker, and the Fc region can be incorporated into a vector and produced using an expression cell. It can also be produced, for example, by the procedure described in 1.2 below.
  • the heavy chain variable region may comprise, for example, an amino acid sequence as shown in SEQ ID NO: 25, 27, 29, 31, 33, or 35, and the light chain variable region may comprise an amino acid sequence as shown in SEQ ID NO: 26, 28, 30, 32, 34, or 36.
  • the heavy chain variable region and the light chain variable region may, for example, comprise an amino acid sequence having 90% or more homology to the amino acid sequences shown in SEQ ID NOs: 25 and 26, respectively, or may comprise an amino acid sequence having a deletion, substitution, insertion or addition of up to several amino acids to the amino acid sequences shown in SEQ ID NOs: 25 and 26, respectively, or may comprise an amino acid sequence having 90% or more homology to the amino acid sequences shown in SEQ ID NOs: 27 and 28, respectively, or may comprise an amino acid sequence having a deletion, substitution, insertion or addition of up to several amino acids to the amino acid sequences shown in SEQ ID NOs: 27 and 28, respectively, or may comprise an amino acid sequence having 90% or more homology to the amino acid sequences shown in SEQ ID NOs: 29 and 30, respectively, or may comprise an amino acid sequence having a deletion, substitution, insertion or addition of up to several amino acids to the amino acid sequences shown in SEQ ID NOs: 29 and 30, respectively.
  • Each of the amino acid sequences may have an amino acid sequence having 90% or more homology to the amino acid sequences shown in SEQ ID NOs: 31 and 32, each of which may have an amino acid sequence having a deletion, substitution, insertion or addition of up to several amino acids to the amino acid sequences shown in SEQ ID NOs: 31 and 32, each of which may have an amino acid sequence having 90% or more homology to the amino acid sequences shown in SEQ ID NOs: 33 and 34, each of which may have an amino acid sequence having a deletion, substitution, insertion or addition of up to several amino acids to the amino acid sequences shown in SEQ ID NOs: 33 and 34, each of which may have an amino acid sequence having 90% or more homology to the amino acid sequences shown in SEQ ID NOs: 35 and 36, each of which may have an amino acid sequence having a deletion, substitution, insertion or addition of up to several amino acids ....
  • the heavy chain variable region may have, for example, FR1 to 4 having the amino acid sequence of FR1 to 4 in the amino acid sequence shown in SEQ ID NO: 25, 27, 29, 31, 33, or 35, an amino acid sequence having 90% or more homology to that amino acid sequence, or an amino acid sequence having a deletion, substitution, insertion or addition of up to a few amino acids to that amino acid sequence, and CDR1 to 3 having an amino acid sequence that matches the amino acid sequence of CDR1 to 3 in the amino acid sequence shown in SEQ ID NO: 25, 27, 29, 31, 33, or 35.
  • the light chain variable region may have, for example, FR1 to 4 having the amino acid sequence of FR1 to 4 in the amino acid sequence shown in SEQ ID NO: 26, 28, 30, 32, 34, or 36, an amino acid sequence having 90% or more homology to that amino acid sequence, or an amino acid sequence having a deletion, substitution, insertion, or addition of up to a few amino acids from that amino acid sequence, and CDR1 to 3 having an amino acid sequence that matches the amino acid sequence of CDR1 to 3 in the amino acid sequence shown in SEQ ID NO: 26, 28, 30, 32, 34, or 36.
  • the Fc region may contain, for example, the amino acid sequence shown in SEQ ID NO: 37, 38, or 45, an amino acid sequence having 90% or more homology to that amino acid sequence, or an amino acid sequence having up to a few amino acid deletions, substitutions, insertions, or additions to that amino acid sequence.
  • the first constant region may comprise, for example, the amino acid sequence shown in SEQ ID NO: 43, an amino acid sequence having 90% or more homology to that amino acid sequence, or an amino acid sequence having up to a few amino acid deletions, substitutions, insertions or additions to that amino acid sequence.
  • the second constant region may comprise, for example, the amino acid sequence shown in SEQ ID NO: 41, an amino acid sequence having 90% or more homology to that amino acid sequence, or an amino acid sequence having up to a few amino acid deletions, substitutions, insertions or additions to that amino acid sequence.
  • the homology (%) may be calculated, for example, by calculating the percentage of homologous amino acids between multiple amino acid sequences according to methods known in the art. Before calculating the percentage, the sequences to be compared are aligned, and gaps are introduced into parts of the sequences if necessary to maximize the percentage of homologous/identical amino acids. Alignment methods, percentage calculation methods, and related computer programs are well known in the art (e.g., BLAST, GENETYX, etc.). In this specification, homology includes identity, and the percentage of homology can be replaced with the percentage of identity. Homology may be expressed as (number of homologous residues/number of residues in the amino acid sequence to be compared) x 100.
  • the homology may be expressed as a value measured using the default settings of BLASTP (The BLAST Sequence Analysis Tool. The NCBI Handbook, 2nd edition. March 15, 2013.; Altschul et al., Nucleic Acids Res0. 1997 Sep 1;25(17):3389-402).
  • the above 90% or more may be, for example, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%, or may be any of these values or more, or within a range between any two of these values. From the viewpoint of maintaining functional equivalence, this percentage is preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, and particularly preferably 98% or more. In one embodiment of the present invention, the above several or less may be, for example, 15, 10, 8, 6, 5, 4, 3, 2, 1, or 0, or may be any of these values or less, or within a range between any two of these values. From the viewpoint of maintaining functional equivalence, this number is preferably 15 or less, more preferably 10 or less, and particularly preferably 5 or less.
  • conservative amino acid substitutions are preferred when substitutions are made to the original sequence.
  • conservative amino acid substitutions involve replacing an amino acid residue with an amino acid residue having a side chain of similar properties.
  • Amino acid residues are classified into several families based on their side chains, such as basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan).
  • Conservative amino acid substitutions are preferably substitutions between amino acid residues within the same family.
  • a polynucleotide or vector encoding the above CD39-binding domain or multispecific antigen-binding molecule (e.g., having any of the above CDR sets (a) to (d)) is provided.
  • a transformant can be produced by introducing this polynucleotide or vector into a cell.
  • the transformant may be a human cell or a non-human mammalian cell (e.g., a monkey, etc.). Examples of mammalian cells include Chinese hamster ovary cells (CHO cells), monkey cells COS-7, and human embryonic kidney cells (e.g., HEK293 cells).
  • the transformant may be Escherichia bacteria, yeast, etc.
  • the polynucleotide or vector may be constructed so as to be capable of expressing an anti-CD39 antibody.
  • the polynucleotide or vector may include components necessary for protein expression, such as a promoter, an enhancer, an origin of replication, or an antibiotic resistance gene.
  • the above vectors may be, for example, plasmids derived from E. coli (e.g., pET-Blue), plasmids derived from Bacillus subtilis (e.g., pUB110), yeast-derived plasmids (e.g., pSH19), animal cell expression plasmids (e.g., pA1-11, pcDNA3.1-V5/His-TOPO), bacteriophages such as ⁇ phage, vectors derived from viruses, etc.
  • the vector may be an expression vector or may be circular.
  • polynucleotides or vectors can be introduced into cells by, for example, the calcium phosphate method, lipofection, electroporation, adenovirus-based methods, retrovirus-based methods, or microinjection (New Genetic Engineering Handbook, 4th Revised Edition, Yodosha Publishing (2003): 152-179).
  • Antibodies can be produced using cells by, for example, the method described in "Protein Experiment Handbook, Yodosha Publishing (2003): 128-142.”
  • a method for producing a CD39-binding domain or a multispecific antigen-binding molecule comprising a step of growing cells containing a polynucleotide or vector according to an embodiment of the present invention.
  • the growing step comprises a culturing step.
  • This production method may also comprise a step of recovering the CD39-binding domain or the multispecific antigen-binding molecule.
  • This production method may also comprise a step of preparing a cell culture medium.
  • This production method may also comprise a step of purifying the CD39-binding domain or the multispecific antigen-binding molecule.
  • the CD39-binding domain or multispecific antigen-binding molecule can be purified using, for example, ammonium sulfate precipitation, ethanol precipitation, protein A, protein G, gel filtration chromatography, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, or lectin chromatography (Protein Experiment Handbook, Yodosha (2003): 27-52.).
  • a composition comprising the above-mentioned CD39-binding domain or multispecific antigen-binding molecule (e.g., having any of the above-mentioned CDR sets (a) to (d)).
  • Use of this composition can produce an excellent antitumor effect.
  • the components contained in this composition are not particularly limited, and may include, for example, a buffer solution.
  • One or more of the various embodiments of the inhibitor and pharmaceutical composition described below may be applied to this composition.
  • This composition includes a composition for suppressing the proliferation of malignant tumor cells, activating immune cells, promoting cytokine production by immune cells, or promoting the release of cytolytic granules.
  • the cytokine includes, for example, IL-2, TNF- ⁇ , or IFN- ⁇ .
  • the cytolytic granule includes, for example, Granzyme B or Perforin.
  • a method for inhibiting the proliferation of malignant tumor cells comprising a step of contacting malignant tumor cells (e.g., CD39-expressing malignant tumor cells) with the above-mentioned CD39-binding domain or multispecific antigen-binding molecule (e.g., having any of the above-mentioned CDR sets (a) to (d)).
  • malignant tumor cells e.g., CD39-expressing malignant tumor cells
  • multispecific antigen-binding molecule e.g., having any of the above-mentioned CDR sets (a) to (d)
  • the occurrence of immune cell activation may be evaluated, for example, by an increase in the cytotoxicity of immune cells against cancer cells, an increase in cytokine secretion from immune cells, or an increase in the expression of PD1 (programmed cell death-1) in CD4- or CD8-positive T cells.
  • Immune cell activation may be, for example, an increase in the cytotoxicity of immune cells against cancer cells, an increase in cytokine secretion from immune cells, promotion of the proliferation of CD4- or CD8-positive T cells, or activation accompanied by an increase in the expression of PD1 in CD4- or CD8-positive T cells.
  • a pharmaceutical composition that includes the above CD39-binding domain or multispecific antigen-binding molecule (e.g., having any of the above CDR sets (a) to (d)).
  • This pharmaceutical composition may include one or more pharmacologically acceptable carriers.
  • the pharmaceutical composition includes, for example, a pharmaceutical composition for treating malignant tumors. Malignant tumors include CD39-positive malignant tumors.
  • a method for treating a disease includes a step of administering the above CD39-binding domain or multispecific antigen-binding molecule (e.g., having any of the above CDR sets (a) to (d)) to a patient.
  • the treatment includes, for example, treatment of malignant tumors and cancer immunotherapy. From another perspective, according to one embodiment of the present invention, use of the above CD39-binding domain or multispecific antigen-binding molecule for producing a pharmaceutical composition is provided.
  • the treatment may be carried out by the anti-tumor activity resulting from the binding of the multispecific antigen-binding molecule to multiple types of antigens.
  • kits that includes the above-mentioned CD39-binding domain or multispecific antigen-binding molecule (e.g., having any of the above-mentioned CDR sets (a) to (d)).
  • the use of this kit can produce an excellent antitumor effect.
  • This kit includes kits for treating malignant tumors, inhibiting the proliferation of malignant tumor cells, activating immune cells, promoting cytokine production by immune cells, or promoting the release of cytolytic granules.
  • This kit may include, for example, an instruction manual, a buffer solution, a container, or packaging.
  • the treatment includes exerting a symptom-improving effect, a suppressive effect, or a preventive effect on the patient's disease or one or more symptoms associated with the disease.
  • the pharmaceutical composition may be produced, for example, by mixing an active ingredient with one or more pharmacologically acceptable carriers and using any method known in the technical field of pharmaceuticals.
  • the pharmaceutical composition may be used in any form as long as it is used for treatment, and may be the active ingredient alone or a mixture of the active ingredient and any ingredient.
  • the form of the carrier is not particularly limited, and may be, for example, a solid or liquid (e.g., a buffer solution).
  • the content of the carrier may be, for example, a pharmaceutical effective amount.
  • the effective amount may be, for example, an amount sufficient for pharmaceutical stability or delivery of the active ingredient.
  • the dosage, administration interval, administration method, and administration route are not particularly limited, and may be appropriately selected depending on the age, weight, symptoms, target organ, etc. of the patient.
  • the pharmaceutical composition preferably contains a therapeutically effective amount, or an effective amount of the active ingredient that exerts the desired effect.
  • the subject includes a human or a non-human mammal (e.g., one or more species of monkey, marmoset, or chimpanzee).
  • the patient may also be a patient diagnosed with a malignant tumor or a patient in need of treatment for a malignant tumor.
  • the malignant tumor cell proliferation inhibitory effect may be evaluated, for example, by observing the change over time in malignant tumor cell proliferation after administration of the pharmaceutical composition.
  • the state in which cell proliferation is inhibited includes a state in which the proliferation rate of the test cells is significantly decreased compared to before treatment with the pharmaceutical composition.
  • the proliferation rate may be measured, for example, using absorbance as an index, or may be determined from image data.
  • the malignant tumor therapeutic effect may be evaluated, for example, by observing the decrease in tumor weight after administration of the pharmaceutical composition. In this case, it may be determined that there is a therapeutic effect when the tumor weight is significantly decreased compared to before administration of the pharmaceutical composition or when the negative control is administered.
  • the malignant tumor therapeutic effect may be measured, for example, using the amount of a malignant tumor marker in a patient or a patient-derived sample as an index. In this case, it may be determined that there is a therapeutic effect when the amount of the marker is significantly decreased compared to before administration of the pharmaceutical composition or when the negative control is administered.
  • the tumor weight or the amount of the marker after administration of the pharmaceutical composition may be decreased to 0.9, 0.7, 0.5, 0.3, or 0.1 times or less compared to before administration or when the negative control is administered.
  • the therapeutic effect may be evaluated by imaging diagnosis.
  • the malignant tumor includes, for example, a tumor that develops as a result of mutation of a normal cell.
  • Malignant tumors can arise from any organ or tissue in the body.
  • the malignant tumor includes, for example, one or more types selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, kidney cancer, adrenal cancer, biliary tract cancer, breast cancer, colon cancer, small intestine cancer, ovarian cancer, uterine cancer, bladder cancer, prostate cancer, ureter cancer, renal pelvis cancer, ureter cancer, penile cancer, testicular cancer, brain tumor, central nervous system cancer, peripheral nervous system cancer, head and neck cancer, glioma, glioblastoma multiforme, skin cancer, melanoma, thyroid cancer, salivary gland cancer, malignant lymphoma, carcinoma, sarcoma, myeloma, and hematological malignant tumor.
  • the malignant tumor includes a CD39-positive malignant tumor
  • the amino acid sequence homology between two different types of antigens may be, for example, 90, 80, 70, 60, 50, or 40%, or may be less than any of these values, or within a range of any two of these values.
  • the binding domain when the "name of a protein" is immediately followed by a "binding domain,” the binding domain includes a domain that recognizes the protein or has binding properties to the protein.
  • a CD39 binding domain includes a domain that recognizes CD39 or has binding properties to CD39. To more clearly describe the properties of the domain, it can also be written as a CD39 binding domain that recognizes CD39.
  • multiplex includes, for example, double, triple, or quadruple.
  • an antigen on a cell surface, an antigen on a cell membrane, and an antigen on a cell may be used with substantially the same intention and may be used interchangeably.
  • a multispecific antigen-binding molecule and a multispecific molecule may be used with substantially the same intention and may be used interchangeably.
  • a first (or second) binding domain and a first (or second) antigen-binding domain may be used with substantially the same intention and may be used interchangeably.
  • an antigen includes, for example, one that may have antigenicity.
  • an antigen-binding molecule includes, for example, a molecule that has binding affinity to at least one antigen.
  • a multispecific antigen-binding molecule that has specificity for CD39 is a molecule that has binding affinity to CD39, and therefore can be said to be a type of antigen-binding molecule.
  • amino acid is a general term for an organic compound having an amino group and a carboxyl group.
  • an antibody according to an embodiment of the present invention contains a "specific amino acid sequence"
  • any of the amino acids in the amino acid sequence may be chemically modified.
  • Any of the amino acids in the amino acid sequence may form a salt or a solvate.
  • Any of the amino acids in the amino acid sequence may be L-type or D-type. Even in such cases, the antibody according to an embodiment of the present invention can be said to contain the above-mentioned "specific amino acid sequence”.
  • N-terminal modifications e.g., acetylation, myristoylation, etc.
  • C-terminal modifications e.g., amidation, glycosylphosphatidylinositol addition, etc.
  • side chain modifications e.g., phosphorylation, sugar chain addition, etc.
  • the bond may be either a covalent bond or a non-covalent bond, for example, an ionic bond, a hydrogen bond, a hydrophobic interaction, or a hydrophilic interaction.
  • "significantly” may mean, for example, that a statistically significant difference is assessed using a Student's t-test (one-tailed or two-tailed) and the difference is p ⁇ 0.05 or p ⁇ 0.01. Alternatively, it may mean that a substantial difference is present.
  • (a), (b), (c) or (d) is synonymous with one or more selected from the group consisting of (a) to (d).
  • Example 1.1 Preparation of recombinant human CD39 Recombinant human CD39 was transiently expressed in FS293 cells (Thermo Fisher Scientific) and purified. Details are as follows. The extracellular domain (amino acid numbers 38 to 478) (SEQ ID NO: 60) of human CD39 (Accession No. NM_001776.6/ NP_001767.3) (SEQ ID NO: 61) was inserted into an expression vector, and transformed into FS293 cells by electroporation using MaxCyte-STX (MaxCyte), and cultured for 4-6 days. Recombinant human CD39 in the culture supernatant was batch-purified with Ni-NTA agarose resin (FujiFilm-Wako), and then purified by size exclusion chromatography.
  • Example 1.2 Preparation of mouse anti-human CD39 antibodies Monoclonal antibodies that specifically bind to human CD39 were prepared from the spleen or lymph nodes of immunized mice using the phage display method. Details are as follows. Mice (BALB/c or MRL/lpr) were immunized with recombinant human CD39 (in house/Example 1.1) or human CD39 antigen transiently expressed Expi293 cells, and the increase in serum antibody titer was confirmed, and the spleen or lymph nodes were collected. Total RNA was extracted from the spleen or lymph nodes of the immunized mice, converted to cDNA, and the antibody gene sequences (VH and V ⁇ ) were amplified by PCR.
  • VH and V ⁇ antibody gene sequences
  • VH and V ⁇ were linked with a linker to form single chain Fv (hereinafter referred to as scFv), and inserted into a phagemid derived from pTZ19R.
  • E. coli DH12S strain
  • scFv-inserted phagemid and further infected with helper phage (M13KO7) to prepare an scFv phage library (size: about 1 x 10 8 types).
  • the scFv antibody phage library was prepared by panning with recombinant human CD39, and the phagemid after panning was extracted, the scFv portion was amplified by PCR, and transferred to an scFv secretion expression vector. Since E.
  • the above four scFvs were linked to a modified antibody Fc region (sequence number 37, Fc-LALA with L234A and L235A mutations in the Fc region of human IgG1) with a short linker in the form of an scFv-Fc-LALA antibody, and expressed in ExpiCHO cells (Thermo Fisher Scientific) and affinity purified using a Protein A column.
  • the clone IDs of the four anti-human CD39 antibodies obtained were P4_sc, T86_sc, I67_sc, or Tre291_sc.
  • These four anti-human CD39 antibodies are derived from P4, T86, I67, or Tre291, respectively, and have the same amino acid sequences of the CDRs.
  • Example 1.3 Evaluation of CD39 inhibitory activity
  • CD39 inhibitory activity was evaluated by ATP quantification using wild-type SKMEL28 cells expressing human CD39. Details are as follows. SKMEL28 cells were prepared at 5x103 cells/well using E-MEM medium, and 50 ⁇ l of each were seeded on a 96-well V-bottom plate. 50 ⁇ l of each of the dilution series of various antibodies was added thereto, and the plate was left to stand in an incubator at 37°C for 1 hour. Next, 5 ⁇ l of ATP (SIGMA, A2383) prepared at 200 ⁇ M in E-MEM medium was added, and the plate was left to stand at room temperature for 30 minutes.
  • SIGMA SIGMA, A2383
  • the plate was then centrifuged at 700 g for 3 minutes, and 50 ⁇ l of the supernatant was collected into a 96-well polystyrene (white) plate.
  • 50 ⁇ l of CellTiter-Glo (registered trademark) 2.0 (Promega, G9242) for ATP quantification was added to the culture supernatant, left at room temperature for 10 minutes, and the amount of ATP was measured by luminescence detection using a microplate reader.
  • the ATP remaining value of a well in which cells were not seeded was set to 100%, and the ATP remaining value of a well in which cells were seeded and no antibody was added was set to 0%, and the inhibition rate of ATP decomposition by various antibodies was calculated from the ratio of the ATP remaining value of the measurement sample, and the inhibitory activity of the antibodies against ATP decomposition of human CD39 was evaluated.
  • Example 1.4 Epitope binning To classify the anti-human CD39 antibodies obtained in Example 1.2 by epitope, epitope binning was performed by intermolecular interaction analysis by surface plasmon resonance (SPR) using Biacore 8K (Cytiva). Details are as follows.
  • Recombinant human CD39 (in house) was captured on a Ni-NTA sensor chip, and the six anti-human CD39 antibodies were added as primary antibodies and allowed to bind until saturation.Then, the six antibodies were added as secondary antibodies and the presence or absence of binding reaction was determined.
  • the results are shown in Figure 1.
  • the antibodies were classified into four epitope bins: (1) P4_sc, I67_sc, and Tre291c_sc, (2) T86_sc, (3) I-394, and (4) 31414. This indicates that the four anti-human CD39 antibodies obtained in Example 1.2 recognize epitopes different from those of conventional antibodies. Furthermore, among the four, T86_sc was shown to recognize a unique epitope.
  • Example 1.5 Recombinant antigen binding ability of anti-human CD39 antibodies
  • the affinity of the anti-human CD39 antibodies obtained in Example 1.2 to human CD39 was measured by interaction analysis using surface plasmon resonance (SPR) using Biacore 8K. Details are as follows.
  • the four anti-human CD39 antibodies prepared were captured on a sensor chip (Cytiva, #29234600) immobilized with anti-human IgG antibodies, and recombinant human CD39 (in house) was used as the analyte.
  • Example 1.6 Analysis of binding of anti-human CD39 antibody to antigen on cell membrane
  • the binding of the anti-human CD39 antibody obtained in Example 1.2 to human CD39 expressed on the cell membrane was analyzed by flow cytometry using human CD39 stably expressing HEK293T cells. Details are as follows. Human CD39 expressing HEK293T cells were sorted into a 96-well V-bottom plate at 2x105 cells/well and washed once with 200 ⁇ l of PBS(-). Next, a dilution series of the anti-human CD39 antibody was prepared in five 10-fold dilutions in Staining Buffer (PBS(-), 1% BSA, 0.09% NaN3 ), and 100 ⁇ l/well of each was added to the cells.
  • PBS(-) Staining Buffer
  • Example 2.1 Preparation of CD39/4-1BB bispecific molecules
  • a bispecific molecule was prepared based on the anti-human CD39 antibody obtained in Example 1.2.
  • the bispecific molecule was designed to have a first antigen-binding domain (CD39-binding domain) targeting human CD39 and a second antigen-binding domain (4-1BB-binding domain) targeting human 4-1BB, an immune cell surface antigen (schematic diagram is shown in FIG. 4).
  • the details of the preparation procedure are as follows.
  • a first vector expressing each of the four anti-human CD39 antibodies (in the form of scFv-Fc) obtained in Example 1.2 was prepared.
  • a second vector expressing a trimer of the extracellular domain (amino acid sequence of positions 71 to 254 (SEQ ID NO: 39)) of the ligand for human 4-1BB (4-1BBL; Accession No. NM_003811.3/ NP_003802.1) (SEQ ID NO: 40) was prepared.
  • a polypeptide chain (SEQ ID NO: 42) in which a 4-1BBL monomer and a human IgG C ⁇ chain (SEQ ID NO: 41) are linked by a short linker, and a polypeptide chain (SEQ ID NO: 44) in which a 4-1BBL dimer linked by a short linker and a human IgG CH chain (SEQ ID NO: 43) are linked by a short linker are expressed from the second vector, and a trimer is formed by disulfide bonding between these polypeptide chains.
  • a hole mutation was introduced into the Fc region of the anti-human CD39 antibody (Hole mutated Fc region: SEQ ID NO: 38) out of Knob-into-Hole (US7183076B2, Knob: Seq No.2, Hole: Seq No.3), and a knob mutation was introduced into the Fc region of the human 4-1BBL trimer (Knob mutated Fc region: SEQ ID NO: 45).
  • the vector expressing the obtained anti-human CD39 antibody and the vector expressing the human 4-1BBL trimer were co-transfected into ExpiCHO cells (Thermo Fisher Scientific) and expressed.
  • the CD39/4-1BB bispecific molecules were purified by anti-IgG-CH1 column (Thermo Fisher Scientific, 494346201), size exclusion chromatography, and ion exchange chromatography.
  • the clone IDs of the obtained four bispecific molecules were P4_4-1BBL, T86_4-1BBL, I67_4-1BBL, or Tre291_4-1BBL.
  • the CD39-binding domains of these four bispecific molecules were derived from P4_sc, T86_sc, I67_sc, or Tre291_sc, respectively, and the amino acid sequences of the CDRs were the same as those of the four bispecific molecules.
  • Example 2.2 Affinity measurement for human CD39 and 4-1BB
  • Example 2.3 Measurement of binding to human cancer cell lines
  • the binding of the CD39/4-1BB bispecific molecule obtained in Example 2.1 to human CD39 expressed on the cell membrane was analyzed by flow cytometry using cancer cells expressing human CD39 (OAW42 cells (ECACC: 85073102) or SKMEL28 cells (ATCC: HTB-72)). Details are as follows. OAW42 cells or SKMEL28 cells were sorted into a 96-well V-bottom plate at 2x105 cells/well and washed once with 200 ⁇ l of PBS(-).
  • a dilution series of the CD39/4-1BB bispecific molecule was prepared in five 10-fold dilutions in Staining Buffer (PBS(-), 1% BSA, 0.09% NaN3 ), and 100 ⁇ l/well of each was added to the cells. After standing at 4°C for 1 hour, the plate was washed once with staining buffer, and 100 ⁇ l/well of staining antibody (PE AffiniPure F(ab')2 Fragment Goat Anti-Human IgG, Fc ⁇ fragment specific (Jackson ImmunoResearch, #109-116-170) diluted 25-fold with staining buffer was added to the cells.
  • Staining Buffer PBS(-), 1% BSA, 0.09% NaN3
  • the plate was washed twice with staining buffer, and 50 ⁇ l of Fixation Buffer (BioLegend, #420801) was added and the plate was left to stand at room temperature for 20 minutes for fixation.
  • the stained cells were suspended in staining buffer, and the fluorescence intensity was measured using a flow cytometer.
  • the geometric mean fluorescence intensity (gMFI) corresponding to each bispecific molecule concentration was plotted, and the Kd value was calculated.
  • PBMCs derived from healthy volunteers were suspended in Assay medium and added to the 96-well plate in an amount 10 times that of the target cells.
  • CD39/4-1BB bispecific molecules or isotype_4-1BBL as a control were added at a final concentration of 10 ⁇ g/ml.
  • P4_4-1BBL, T86_4-1BBL, I67_4-1BBL, or Tre291_4-1BBL were used as CD39/4-1BB bispecific molecules.
  • Anti-CD3 antibody (OKT3, BioLegend, #317326) was then added to a final concentration of 1 nM, and co-culture was performed for 2 days at 37°C and 5% CO2 .
  • Example 3.1 Preparation of humanized antibodies Humanization of the anti-human CD39 antibodies prepared in Example 1.2 was carried out by the CDR grafting method. Details are as follows. Among the anti-human CD39 antibodies, P4_sc and T86_sc, which were particularly shown to promote cytokine production, were humanized by CDR grafting using Discovery Studio (Dassault Systèmes). Of the multiple candidates obtained for each, those with affinity and biological activity equal to or greater than those of the original mouse antibody were selected. The humanized antibodies were prepared in the form of scFv-Fc-LALA type antibodies by the method described in Example 1.2. The clone IDs of the two humanized antibodies obtained were HuP4_IB and HuT86_IF. These two humanized antibodies were derived from P4_sc and T86_sc, respectively, and the amino acid sequences of the CDRs are the same as those of the two humanized antibodies.
  • Example 3.2 Recombinant antigen-binding ability of humanized anti-human CD39 antibodies
  • Example 4.4 Measurement of cytokine production in a co-culture system of SKMEL28 cells and PBMCs ⁇ br/>The effect of the CD39/4-1BB bispecific molecule obtained in Example 4.1 on the antitumor activity in a co-culture system of cancer cells and PBMCs was evaluated. Details are as follows. Target cells (SKMEL28) were suspended in Assay medium (E-MEM medium containing 10% FCS and 1% penicillin-streptomycin) and seeded on a 96-well plate. Next, PBMCs derived from healthy volunteers were suspended in Assay medium and added to the 96-well plate in an amount 1.6 times that of the target cells.
  • Assay medium E-MEM medium containing 10% FCS and 1% penicillin-streptomycin
  • IL-2, TNF- ⁇ , and IFN- ⁇ in the culture supernatant were measured by Luminex.
  • a calibration curve was created using recombinant IL-2, TNF- ⁇ , and IFN- ⁇ with known concentrations, and the concentration of each cytokine was calculated.
  • Example 4.5 Measurement of cell proliferation inhibitory effect on SKMEL28 cell line
  • the CD39/4-1BB bispecific molecule obtained in Example 4.1 was evaluated for its antitumor effect in a co-culture system of PBMC and cancer cells. Details are as follows. HuP4_IB_4-1BBL, HuT86_IF_4-1BBL, 31414_4-1BBL, and I-394_4-1BBL were used as CD39/4-1BB bispecific molecules for evaluation, and isotype_4-1BBL was used as a control.
  • the SKMEL28 cell line was suspended in E-MEM medium containing 10% FCS and 1% penicillin-streptomycin, seeded on a 96-well plate, and cultured under conditions of 37°C and 5% CO2 .
  • PBMCs from healthy volunteers were suspended in E-MEM medium containing 10% FCS and 1% penicillin-streptomycin, and then added to a 96-well plate so that the number of PBMCs was 1.6 times the number of cancer cells seeded the previous day.
  • the bispecific molecule or isotype_4-1BBL for evaluation was added at a final concentration of 1 ⁇ g/ml to the wells containing the cancer cells and PBMCs.
  • Anti-CD3 antibody was then added to a final concentration of 1 nM, and co-culture was performed for 7 days at 37°C and 5% CO2 . After co-culture, the culture supernatant and non-adherent cells were collected, and the wells were washed twice with PBS, and 70 ⁇ L of PBS was added. An additional 70 ⁇ L of CellTiter-Glo® 2.0 (Promega, G9243) was added and the mixture was shaken at room temperature for 10 minutes. Then, 100 ⁇ L of the contents of each well was dispensed into a white 96-well plate, and the amount of ATP derived from live cells was measured by luminescence detection using a microplate reader.
  • Example 5.1 Preparation of CD39/CD3 bispecific molecule
  • a bispecific molecule was prepared based on the anti-human CD39 antibody obtained in Example 3.1.
  • the bispecific molecule was designed to have a first antigen-binding domain (CD39-binding domain) targeting human CD39 and a second antigen-binding domain (CD3-binding domain) targeting human CD3.
  • the details of the preparation procedure are as follows.
  • the vector prepared in Example 4.1 was used as the first vector expressing the anti-human CD39 antibody (in the form of scFv-Fc) obtained in Example 3.1.
  • a second vector expressing an antibody against human CD3 (OKT3) was prepared.
  • a polypeptide chain consisting of the V ⁇ chain of OKT3 (SEQ ID NO: 53) and the C ⁇ chain of human IgG (SEQ ID NO: 41), and a polypeptide chain (SEQ ID NO: 68) consisting of the VH chain of OKT3 (SEQ ID NO: 52) and the CH chain of human IgG (SEQ ID NO: 43) were expressed, and a dimer was formed by disulfide bonding between these polypeptide chains.
  • a knob mutation was introduced into the Fc region of the anti-human CD3 antibody (Knob-into-Hole (US7183076B2, Knob: Seq No.2, Hole: Seq No.3) so that the anti-human CD39 antibody and the anti-human CD3 antibody would form a heterodimer (Knob-mutated Fc region: SEQ ID NO: 45).
  • a vector expressing the anti-human CD39 antibody and a vector expressing the anti-human CD3 antibody were simultaneously introduced into ExpiCHO cells (Thermo Fisher Scientific) and expressed.
  • the CD39/CD3 bispecific molecule was purified by anti-IgG-CH1 column (Thermo Fisher Scientific, 494346201) and cation exchange chromatography.
  • Example 5.3 Measurement of binding to human cancer cell lines
  • the binding of the CD39/CD3 bispecific molecule OKT3-HuT86_IF_Fsc obtained in Example 5.1 to human CD39 expressed on the cell membrane was measured by the method described in Example 2.3.
  • HuT86_IF_4-1BBL prepared in Example 4.1 was used as a control.
  • the geometric mean fluorescence intensity (gMFI: geometric MFI) corresponding to the bispecific molecule concentration was plotted, and the Kd value was calculated.
  • Example 5.4 Cytotoxicity measurement against SKMEL28 cell line
  • the effect of the CD39/CD3 bispecific molecule obtained in Example 5.1 on the antitumor activity in a co-culture system of PBMC and cancer cells was measured by the method described in Example 4.5.
  • anti-CD3 antibody OKT3, BioLegend, #317326
  • the number of PBMC cells added was the same as that of the target cells.
  • the amount of ATP derived from live cells in a well to which the bispecific molecule and anti-CD3 antibody were not added was set to 100%, and the viable cell survival rate in each well was calculated from the amount of ATP in the measurement sample, and the value obtained by subtracting the viable cell survival rate from 1 was used to evaluate the cancer cell cytotoxicity of the bispecific molecule and anti-CD3 antibody.
  • Example 5.5 Measurement of cytokine production and cytolytic granule release in SKMEL28 cells and PBMC co-culture system Using the culture supernatant of Example 5.4, the cytokine production and cytolytic granule release were measured by the method described in Example 4.4. However, in the CD39/CD3 bispecific molecule addition group, anti-CD3 antibody (OKT3, BioLegend, #317326) was not added. In addition, the number of PBMC cells added was the same as that of the target cells. Granzyme B and Perforin were measured using MILLIPLEX MAP 7-Plex Human CD8+/Cytokine Magnetic Bead Panel (Millipore, #HCD8MAG15K17PMX). Standard curves were created using recombinant IL-2, TNF- ⁇ , IFN- ⁇ , Granzyme B, and Perforin with known concentrations, and the concentrations of each cytokine and cytolytic granule were calculated.
  • Example 6.1 Measurement of T cell activation in a co-culture system of SKMEL28 cells and PBMCs The effect of the CD39/CD3 bispecific molecule obtained in Example 5.1 on effector cells in a co-culture system of PBMCs and cancer cells was evaluated. Details are as follows. OKT3-HuT86_IF_Fsc and OKT3-I-394_Fsc were used as CD39/CD3 bispecific molecules for evaluation, and OKT3 was used as a control.
  • the SKMEL28 cell line was suspended in E-MEM medium containing 10% FCS and 1% penicillin-streptomycin, seeded in a 24-well plate at 2.4x10 ⁇ 4 cells/well, and cultured under conditions of 37°C and 5% CO2.
  • PBMCs from healthy volunteers were suspended in E-MEM medium containing 10% FCS and 1% penicillin-streptomycin, and then added to the wells so that the number of PBMCs was equal to that of the cancer cells seeded the previous day.
  • the bispecific molecule or OKT3 to be evaluated was added at a final concentration of 1 ⁇ g/ml to the wells containing the cancer cells and PBMCs, and co-cultured at 37°C and 5% CO2.
  • Brefeldin A BioLegend
  • the cells were cultured at 37°C and 5% CO2 for 17 hours.
  • the cells were collected in a 96-well V-bottom plate and washed once with 200 ⁇ l of PBS(-).
  • the cells were then washed twice with Intracellular Staining Permeabilization Wash Buffer (BioLegend, #421002), and cytokine staining antibodies (BioLegend, anti-IFN- ⁇ : B27, anti-IL2: MQ1-17H12) were appropriately diluted with Intracellular Staining Permeabilization Wash Buffer, 100 ul of antibodies were added, and the cells were left to stand at 4°C for 40 minutes in the dark. After washing twice with Intracellular Staining Permeabilization Wash Buffer, the cells were suspended in Staining Buffer, and beads for cell counting (Thermo Fisher Scientific, #C36950) were added and analyzed with a flow cytometer.
  • Intracellular Staining Permeabilization Wash Buffer BioLegend, #421002
  • cytokine staining antibodies BioLegend, anti-IFN- ⁇ : B27, anti-IL2: MQ1-17H12
  • the anti-human CD39/CD3 bispecific molecule OKT3-HuT86_IF_Fsc prepared in this example activates and increases T cells in the presence of CD39-expressing cells, and furthermore, that although the CD39 positive fraction in T cells can be the target cells of the anti-human CD39/CD3 bispecific molecule, surprisingly, it has little effect on activated CD39 positive T cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/JP2024/034478 2023-09-26 2024-09-26 Cd39を標的とする多重特異性抗原結合性分子 Ceased WO2025070636A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025549115A JPWO2025070636A1 (cg-RX-API-DMAC7.html) 2023-09-26 2024-09-26

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2023163666 2023-09-26
JP2023-163666 2023-09-26
JP2024-061117 2024-04-04
JP2024061117 2024-04-04

Publications (1)

Publication Number Publication Date
WO2025070636A1 true WO2025070636A1 (ja) 2025-04-03

Family

ID=95201672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/034478 Ceased WO2025070636A1 (ja) 2023-09-26 2024-09-26 Cd39を標的とする多重特異性抗原結合性分子

Country Status (2)

Country Link
JP (1) JPWO2025070636A1 (cg-RX-API-DMAC7.html)
WO (1) WO2025070636A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527138A (ja) * 2018-06-14 2021-10-11 ベス イスラエル デアコネス メディカル センター インコーポレイティッド エクトヌクレオチダーゼの阻害及び抗体媒介性標的膜動輸送を通じてt細胞疲弊を予防又は解除するための組成物及び方法
JP2022537019A (ja) * 2019-06-21 2022-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
WO2023195532A1 (ja) * 2022-04-07 2023-10-12 ブライトパス・バイオ株式会社 ヒトtim-3およびヒトcd39に対する二重特異性抗体およびその用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527138A (ja) * 2018-06-14 2021-10-11 ベス イスラエル デアコネス メディカル センター インコーポレイティッド エクトヌクレオチダーゼの阻害及び抗体媒介性標的膜動輸送を通じてt細胞疲弊を予防又は解除するための組成物及び方法
JP2022537019A (ja) * 2019-06-21 2022-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
WO2023195532A1 (ja) * 2022-04-07 2023-10-12 ブライトパス・バイオ株式会社 ヒトtim-3およびヒトcd39に対する二重特異性抗体およびその用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUMOTO NORIKO, MISHIMA YUJI, NAKAJIMA KANTO, ARAMAKI TAKAHIKO, SHIRAISHI MAMORU, MATSUMURA HARUKA, NAKAMURA NORIHIRO: "1364 Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms", J IMMUNOTHER CANCER, 10 November 2022 (2022-11-10), pages A1413 - A1413, XP093097993, DOI: 10.1136/jitc-2022-SITC2022.1364 *
NORIKO MATSUMOTO, YUJI MISHIMA, KANTO NAKAJIMA, TAKAHIKO ARAMAKI, NORIKO WATANABE, MAMORU SHIRAISHI, HARUKA MATSUMURA, NORIHIRO NA: "Bispecific antibodies against TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms- Presentation", SITC 2022, BRIGHTPATH BIOTHERAPEUTICS CO., LTD., XP009562643, Retrieved from the Internet <URL:https://www.brightpathbio.com/english/file/20221111_sitc2022_bp1212.pdf> *

Also Published As

Publication number Publication date
JPWO2025070636A1 (cg-RX-API-DMAC7.html) 2025-04-03

Similar Documents

Publication Publication Date Title
US10975155B2 (en) CD40L-Fc fusion polypeptides and methods of use thereof
CN109476732B (zh) 三特异性和/或三价结合蛋白
AU2018234810B2 (en) Targeted immunotolerance
JP2021152040A (ja) 新規抗ctla4抗体
JP2024054156A (ja) FcγR非依存性アゴニスト活性がある腫瘍壊死因子(TNF)受容体スーパーファミリー(TNFRSF)受容体活性化抗体融合タンパク質(FcγR非依存性アゴニスト活性があるTNFRSF受容体活性化抗体融合タンパク質;TRAAFFIAA)
TW202400654A (zh) 抗tigit抗體及其作為治療和診斷的用途
JP2021522780A (ja) 拮抗性cd73抗体
TW201920277A (zh) 抗cd39抗體、包含抗cd39抗體之組成物及使用抗cd39抗體之方法
JP2018533371A (ja) 抗tigit抗原結合タンパク質と、その使用方法
JP2019501883A (ja) 抗体およびその使用方法
JP2020504171A (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
TW201639880A (zh) 針對ror1之特異性抗體及嵌合抗原受體
US20190284262A1 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
JP2018527299A (ja) Cd38を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
CN114901691A (zh) Ilt3结合剂及其使用方法
JP2021502360A (ja) 二重特異的融合ポリペプチド及びその使用方法
TWI896517B (zh) 雙專一性抗體及製造與使用其的方法
KR20230035076A (ko) 변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도
TW202216768A (zh) Lair-1結合劑及其使用方法
US20230044381A1 (en) Anti-human programmed death-1 monoclonal antibody
CA3144755A1 (en) Method of inhibiting or activating gamma delta t cells
EP4506368A1 (en) Bispecific antibody to human tim-3 and human cd39, and applications thereof
CN113811545B (zh) 对btn2具有特异性的抗体及其用途
JP2024542879A (ja) Pd-1およびtgf-brii結合ドメインを含む多重特異性結合部位
US20210260159A1 (en) CD40L-Fc FUSION POLYPEPTIDES AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24872421

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025549115

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025549115

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE